cancers Review Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets Alexandros Karagiannakos 1 , Maria Adamaki 1 , Antonis Tsintarakis 1 , Borek Vojtesek 2 , Robin Fåhraeus 2,3,4,5 , Vassilis Zoumpourlis 1, *,† and Konstantinos Karakostis 1,3,6, *,† 1 Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 48 Vassileos Constantinou Avenue, 11635 Athens, Greece; alkarg96@gmail.com (A.K.); madamaki@eie.gr (M.A.); Tsintarakis@hotmail.com (A.T.) 2 Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 65653 Brno, Czech Republic; vojtesek@mou.cz (B.V.); robin.fahraeus@inserm.fr (R.F.) 3 Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France 4 Department of Medical Biosciences, Umeå University, 90185 Umeå, Sweden 5 International Centre for Cancer Vaccine Science, University of Gdansk, 80-822 Gdansk, Poland 6 Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain   * Correspondence: vzub@eie.gr (V.Z.); konstantinos.karakostis@gmail.com (K.K.) † These authors contributed equally to this work. Citation: Karagiannakos, A.; Adamaki, M.; Tsintarakis, A.; Vojtesek, B.; Fåhraeus, R.; Simple Summary: Currently, genomic databases offer a vast amount of information on mutational Zoumpourlis, V.; Karakostis, K. profiles and records of statistically significant genetic associations with diseases. However, the func- Targeting Oncogenic Pathways in the tional interpretation of frequently mutated genes implicated in cancer is essential for the development Era of Personalized Oncology: A and clinical implementation of efficient targeted therapies. This review identifies and describes the Systemic Analysis Reveals Highly most affected signaling pathways that are found deregulated in several cancer types and reports on Mutated Signaling Pathways in corresponding targeted therapies, aiming to unravel literature gaps and to highlight targets of high Cancer Patients and Potential therapeutic potential. To this purpose, we collected gene lists from the TCGA Pan-Cancer Atlas and Therapeutic Targets. Cancers 2022, 14, OncoKB and employed the Onco Query Language (cBioPortal) search, to identify somatic driver 664. https://doi.org/10.3390/ events in 10,439 tumor samples. Each mutation was linked to the affected pathways and to the corre- cancers14030664 sponding tumorigenic potential. Based on this analysis, the 10 most frequently mutated signaling Academic Editor: Constantin pathways were selected for this review. A detailed description of the mechanistic implications of the N. Baxevanis identified mutations, as well as the corresponding cancer types and cognate therapeutic applications Received: 30 December 2021 currently being employed or being under clinical investigation in clinical trials, is discussed. This Accepted: 24 January 2022 review aims to explain how the utilization of available genomic mutation data can be employed for Published: 28 January 2022 the development of targeted therapies, thereby advancing personalized medicine. Publisher’s Note: MDPI stays neutral Abstract: Cancer is the second leading cause of death globally. One of the main hallmarks in cancer with regard to jurisdictional claims in is the functional deregulation of crucial molecular pathways via driver genetic events that lead to published maps and institutional affil- abnormal gene expression, giving cells a selective growth advantage. Driver events are defined iations. as mutations, fusions and copy number alterations that are causally implicated in oncogenesis. Molecular analysis on tissues that have originated from a wide range of anatomical areas has shown that mutations in different members of several pathways are implicated in different cancer types. Copyright: © 2022 by the authors. In recent decades, significant efforts have been made to incorporate this knowledge into daily Licensee MDPI, Basel, Switzerland. medical practice, providing substantial insight towards clinical diagnosis and personalized therapies. This article is an open access article However, since there is still a strong need for more effective drug development, a deep understanding distributed under the terms and of the involved signaling mechanisms and the interconnections between these pathways is highly conditions of the Creative Commons anticipated. Here, we perform a systemic analysis on cancer patients included in the Pan-Cancer Atlas Attribution (CC BY) license (https:// project, with the aim to select the ten most highly mutated signaling pathways (p53, RTK-RAS, lipids creativecommons.org/licenses/by/ metabolism, PI-3-Kinase/Akt, ubiquitination, b-catenin/Wnt, Notch, cell cycle, homology directed 4.0/). Cancers 2022, 14, 664. https://doi.org/10.3390/cancers14030664 https://www.mdpi.com/journal/cancers Cancers 2022, 14, 664 2 of 32 repair (HDR) and splicing) and to provide a detailed description of each pathway, along with the corresponding therapeutic applications currently being developed or applied. The ultimate scope is to review the current knowledge on highly mutated pathways and to address the attractive perspectives arising from ongoing experimental studies for the clinical implementation of personalized medicine. Keywords: molecular oncology; precision medicine; tumor; NGS; clinical implementation; cancer patients; mutations 1. Personalized Therapeutic Strategies Require Understanding of the Underlying Signaling Pathways’ Mechanisms In 2020, over 19 million people were diagnosed with cancer, with mortality rates reach- ing approximately 10 million [1]. This makes cancer one of the most critical health concerns of our times and highlights the urgency for devising new and more effective therapies. In this context, it is critical to comprehend the main routes whereby different cancer types arise and progress. Effective treatments are expected to derive from personalized molecular approaches, especially if one considers that cancer usually arises from a variety of causative mutations. A robust impetus was given towards this direction after the completion of the Human Genome Project (HGP) in 2003 [2,3], and several individualized anti-cancer therapies have been developed and applied since then [4–6]. Cancer can be regarded as a collection of diseases, all of which share a common feature; the deregulation of key signaling cascades that leads to uncontrolled cellular proliferation [7]. Malignancies arise from alterations in the DNA sequence of genes, as well as from epigenetic changes [8–12]. Both changes induce the activation of oncogenes or the inactivation of tumor-suppressor genes, leading to evasion of growth suppressor function, resistance to cell death (apoptosis), uncontrolled cell cycle, immune evasion as well as increased invasive and metastatic potential [13]. Cancer diagnosis is becoming more reliant on the characterization of mutated pathways that can provide vital information to the separation and clustering of cancer types [14]. Several signaling cascades, including the b-catenin/Wnt, RTK/RAS, p53 and Sonic Hedgehog (SHH) pathways, are linked to cancer formation due to genetic variations that often occur in the respective genes [15,16]. Identification of mutations in genes implicated in such pathways has the potential to reveal the causative driver events of carcinogenesis [17]; it therefore constitutes a topic of paramount importance in precision medicine and for the development of efficient tailor- made drug therapies targeting each cancer type at the molecular level. Personalized cancer therapy is a treatment strategy that takes into account the molecu- lar profile of patients in order to stratify them into groups that are more likely to benefit from different therapeutic approaches [18,19]. Especially during the past fifteen years, numerous targeted therapies have been approved, extending the survival rates of cancer patients. For example, administration of monoclonal antibodies such as cetuximab, currently used to treat colorectal cancers expressing the EGFR gene [20], as well as tyrosine kinase inhibitors such as crizotinib, which is used for the treatment of non-small cell lung cancers (NSCLC) that are positive for ALK fusions [21], have been dynamically integrated into oncology practice. In addition to pharmacogenetic approaches, gene editing approaches have also begun to attract a lot of interest and in particular the clustered regularly interspaced short palindrome repeats (CRISPR)/Cas9 system; the latter is currently being tested in multiple clinical trials for its ability to genetically modify immune cells ex vivo (e.g., PD-1 knockout T-cells), and to enhance the anti-cancer immune response when these cells are infused back into the patient [22,23]. Functional studies and clinical implementation of CRISPR/Cas9 are highly anticipated for the development of more effective anti-cancer therapies that target specific genetic alterations, and are thereby capable of restoring their function. Cancers 2022, 14, 664 3 of 32 2. Systemic Analysis Determines Prevalent Mutated Carcinogenic Pathways The aim of this review is to highlight the importance of the underlying mechanisms in crucial carcinogenic signaling pathways. To this purpose, we focus on the signaling pathways that are most frequently found deregulated in cancers. We have specifically focused on cancer-related pathways previously identified by Pan-Cancer Atlas project studies [14,24–28] and have calculated the frequencies of each driver mutation to the corresponding pathways. For our analysis we used publicly available data on 10,439 tumor samples from 32 TCGA Pan-Cancer Atlas studies [29]. Our results suggest that the ten main pathways known to be implicated in cancer development can be sorted in descending order based on their driver mutation frequency, as follows: p53, RTK-RAS, lipids metabolism, PI-3-Kinase/Akt, ubiquitination, b-catenin/Wnt, Notch, cell cycle, homology directed repair (HDR) and splicing. Gene lists were created by collecting data on signaling pathways from the TCGA Pan-Cancer Atlas publications (3004 genes in total, available in https://www.cell.com/pb- assets/consortium/pancanceratlas/pancani3/index.html (accessed on 1 November 2021)). Then, we filtered only those genes that belong to the OncoKB cancer gene list (340 genes), (version update: February 2021). Using the Onco Query Language (OQL) provided by cBioPortal, we searched specifically for somatic driver mutations in these genes in 10,439 mutationally profiled tumor samples (10,066 primary, 364 metastatic and 9 recur- rent) included in 32 TCGA Pan-Cancer Atlas studies. We ascertained that more than 95% of the samples affected by driver events in the genes of interest (7915 out of 8276) belonged to the “primary origin” category, and therefore became the focus of subsequent analyses. Data were extracted from the cBioPortal for Cancer Genomics open-access re- source. Somatic driver mutations were identified in 204 of the 340 cancer genes in this particular dataset, so their corresponding pathways were marked for further analyses. The selection of the driver events was made in line with the definition of cBioPortal (https://www.cbioportal.org/oql#driver (accessed on 1 November 2021)) and OncoPrint (default: OncoKB and CancerHotspots). As such, mutations, fusions and copy number alterations constitute ‘drivers’. Note that germline and somatic modifiers only apply to mutations and that very few studies on the public cBioPortal contain germline data. The types of alterations found in the 7915 samples are the following: frame_shift deletions or in- sertions, fusions, in frame deletions or insertions, missense mutations, nonsense mutations, nonstop mutations, slice regions or sites and translation start sites. Data management, calculations and graph construction were performed using Spyder IDE, a scientific Python development environment. Numerous TCGA Pan-Cancer Atlas efforts have been made to elucidate the genomic background of cancer, each focusing on the deregulation of a differ- ent physiological cellular procedure [14]. Each one of these procedures involves a number of signaling pathways that contain genes with a distinct tumorigenic potential (Figure 1). Furthermore, our mutational data analysis has shown that most cancers are characterized by deregulation of a group of pathways, rather than a single signaling pathway, but in a distinct pattern from other cancer types, while in some tumor types, a subtype-related differential representation of altered pathways or even a stage-dependent pathway pertur- bation also seems to exist (Figure 2). The Python code, as well as the typed query for driver events in the genes of interest using the cBioPortal Onco Query Language (OQL) can be found in the supplementary information (Supplementary Materials S1 and S2). This review therefore focuses on the ten most frequently deregulated signaling path- ways and as such only the results pertaining to these pathways are discussed below. In the next sections, we describe how specific genetic alterations/mutations in encoding genes of a given pathway may lead to carcinogenesis and/or cancer progression. For each pathway, a brief description is provided regarding its implication in cancer development, along with a description of the most highly mutated genes, and their percentile frequencies, as calcu- lated in our analysis. In addition, we list some related targeted therapies that have been approved by the Food and Drug Administration (FDA) and are currently being integrated Cancers 2022, 14, 664 4 of 32 Cancers 2022, 14, x FOR PEER REVIEW into 4 of 34 clinical practice, as well as some emerging therapies which are currently being tested in clinical trials. Figure Figure 1. 1. Somatic driver mutational Somatic driver mutationalfrequency frequencyofof204 204 cancer cancer genes genes involved involved in signaling in 27 27 signaling path- pathways ways implicated in six major cellular procedures. For the calculations, mutational data from 10,439 implicated in six major cellular procedures. For the calculations, mutational data from 10,439 tumor tumor samples were examined. Percentages refer to the total number of samples examined (10,439). samples were examined. Percentages refer to the total number of samples examined (10,439). Cancers 2022, 14, 664 x FOR PEER REVIEW 5 of 34 32 Figure 2. Cont. Cancers 2022, 14, 664 6 of 32 Cancers 2022, 14, x FOR PEER REVIEW 6 of 34 Figure 2. Cont. Cancers 2022, 14, Cancers 2022, 14,664 x FOR PEER REVIEW 77 of of 32 34 Figure 2. Crucial signaling pathways implicated in 25 cancer types/subtypes per disease stage. For Figure 2. Crucial signaling pathways implicated in 25 cancer types/subtypes per disease stage. this analysis, 5283 tumor samples with an available mutational profile and disease stage were ex- For this analysis, 5283 tumor samples with an available mutational profile and disease stage were amined. Here, only signaling pathways altered in at least 20 of the examined samples for each cancer examined. type/subtypeHere, only signaling are shown. pathways N: number altered of samples in at least examined; 20 of the n: number of examined samples samples that harborfor each somatic cancer type/subtype driver mutations are shown. in each signalingN:pathway; number pdm: of samples examined; proportion n: number of samples of samples of a particular that cancer harbor somatic type/subtype driver that mutations harbor in each at least one signaling somatic driverpathway; mutationpdm: proportion in genes of samples of a particular of a signaling pathway. cancer type/subtype that harbor at least one somatic driver mutation in genes of a particular particular signaling pathway. This review therefore focuses on the ten most frequently deregulated signaling path- 3. The ways andp53asPathway such only the results pertaining to these pathways are discussed below. In the next sections, of Components wethe p53 pathway describe functiongenetic how specific cooperatively to ensure that in alterations/mutations theencoding cell will respond genes of aeffectively given pathway against a variety may lead toof stress signalsand/or carcinogenesis that threaten cellular homeostasis cancer progression. For each and genomic pathway, integrity. a brief In this description is process, providedp53 target genes regarding trigger several its implication pathways in cancer linked development, to cancer, along withsuch as cell cycle a description arrest, of the mostsenescence or apoptosis, highly mutated genes, andblood vessel their formation percentile and frequen- the regulation of metabolism [30–34]. The importance of TP53 in cancer cies, as calculated in our analysis. In addition, we list some related targeted therapies that development is evident by the fact that it occupies the first place in the ranking have been approved by the Food and Drug Administration (FDA) and are currently being of genes found to be most frequently integrated altered into clinicalin cancer [35,36]. practice, Indeed, as well the number as some emerging of cancer types/subtypes therapies where which are currently p53 pathway is likely being tested in clinical trials.not perturbed is very small (e.g., uveal melanoma) (Figure 3). In the majority of cancer types, more than 30% of the samples examined harbored driver mutations 3. The p53 in at least one key gene of this pathway, while in some cases this percentage Pathway exceeded 90% (e.g., esophageal squamous cell carcinoma). Even though there is a high Components of the p53 pathway function cooperatively to ensure that the cell will number of cancers that bear a variant in one or more components of the p53 pathway, the respond effectively against a variety of stress signals that threaten cellular homeostasis affected components are specific to three genes in this pathway. We found that among and genomic integrity. In this process, p53 target genes trigger several pathways linked those patients, 93.66% had a driver mutation in TP53, whereas CDKN2A and ATM genes to cancer, such as cell cycle arrest, senescence or apoptosis, blood vessel formation and were affected in 7.71% and 6.27% respectively, dictating the simultaneous presence of the regulation of metabolism [30–34]. The importance of TP53 in cancer development is some of these mutations in a number of cases. TP53 driver mutations can be located in evident by virtually any the fact that region it occupies of the gene, thusthe first place affecting in the ranking the ability of the p53of protein genes found to be most to appropriately frequently interact withaltered either in its cancer protein[35,36]. effectorsIndeed, the number or the DNA of cancertotypes/subtypes [37]. According where our analysis, arginine residues on positions 273, 248 and 175, all of which belong to the DNA-binding domainIn[38], p53 pathway is likely not perturbed is very small (e.g., uveal melanoma) (Figure 3). the majority of cancer types, more than 30% of the samples examined are the most frequently mutated, representing 7.06%, 5.87% and 4.41% of patients that harbored driver muta- tions an have in at least one affected TP53 key generespectively. gene, of this pathway,R273while in some variants have cases this percentage been associated with ex- an ceeded 90% (e.g., esophageal squamous cell carcinoma). Even though increased proliferative and invasive potential, which in the case of R273H, are induced there is a high num- by ber inhibition the of cancersofthat tumor bearsuppressor a variant KLF6 in one[39,40]. or more components Similar of the effects seem p53 pathway, to take place when thea affected components are specific to three genes in this pathway. R248 mutant is present, but this particular mutation leads to a robust binding of certainWe found that among those patients, 93.66% had a driver mutation in TP53, whereas CDKN2A and ATM genes ately interact with either its protein effectors or the DNA [37]. According to our analysis, arginine residues on positions 273, 248 and 175, all of which belong to the DNA-binding domain [38], are the most frequently mutated, representing 7.06%, 5.87% and 4.41% of patients that have an affected TP53 gene, respectively. R273 variants have been associated with an increased proliferative and invasive potential, which in the case of R273H, are Cancers 2022, 14, 664 8 of 32 induced by the inhibition of tumor suppressor KLF6 [39,40]. Similar effects seem to take place when a R248 mutant is present, but this particular mutation leads to a robust binding of certain variants—mainly the mutp53R248Q—to the STAT3 protein, and to the subsequent variants—mainly the mutp53 R248Q activation of the latter [41,42]. The—to R175Ηthe variant, STAT3 protein, and tohand, on the other the subsequent activation is associated with a of the latter [41,42]. The R175H variant, on the other hand, is associated with radical change in p53 conformation which triggers the transactivation of a panel of genes a radical change and in p53 results conformation in elevated which levels c-met protein triggers the and to transactivation the induction ofof a panel tumor of genes invasion, and among results in elevated other events [43,44]. c-met protein levels and to the induction of tumor invasion, among other events [43,44]. Figure 3. Figure Alteration rate 3. Alteration rate of of 27 27 signaling signaling pathways pathways across 36 cancer types/subtypes. types/subtypes.For Forthis thisanalysis, analysis, 10,066 tumor tumor samples samplesof ofprimary primaryorigin originand andwith withavailable available mutational mutational profiles profiles werewere examined examined for for the the presence presence of somatic of somatic driver driver mutations mutations in our in our 204204 genes genes of interest. of interest. Calculations Calculations werewere performed performed by by taking taking into into account account allall thethe available available mutationally mutationally profiled profiled primary primary tumor tumor samples samples ofof thecBioPortal the cBioPor- tal selected studies (10,066 samples) instead of the driver event-harboring mutationally profiled pri- selected studies (10,066 samples) instead of the driver event-harboring mutationally profiled primary mary tumor samples (7915 samples). If for a selected cancer type there were x mutationally profiled tumor samples (7915 samples). If for a selected cancer type there were x mutationally profiled primary primary tumor samples available in the cBioPortal selected studies, then, y samples would bear at tumor least onesamples driver available event in atinleast the cBioPortal one of the selected 204 genesstudies, then, of interest y samples and z sampleswould wouldbear at least harbor one driver driver event in at least one of the 204 genes of interest and z samples would harbor events in genes participating in a selected signaling pathway. The corresponding driver mutational driver events in genesfor rate participating this cancerintype-signaling a selected signaling pathwaypathway. pair The corresponding is calculated driver as (z/x) mutational × 100. rate for Here, only this cancer cancer type-signaling types/subtypes pathway that entail morepair thanis50calculated analyzedas (z/x) ×are samples 100. Here, From shown. only cancer left to types/subtypes right, signaling pathways that entailaremoredisplayed than 50 in descending analyzed orderare samples of shown. total mutational From leftfrequency. n: number to right, signaling of samples pathways are examined. displayed in descending order of total mutational frequency. n: number of samples examined. In addition to missense mutations and other mutation types, the CDKN2A gene is frequently affected by nonsense mutations, in line with our analysis, which demonstrates that R80*, R58*, W110*, E120*, Y44* and E88* together constitute almost a third of cancer cases that harbor a defective CDKN2A gene. Such alterations shut down one of the cell cycle’s checkpoints, as they force the p16INK4a protein to lose its Cdk-binding ability, thereby being unable to prevent the G1/S transition [45–47]. From the remaining two thirds of cases, an aberrant splicing involving the D153 residue appears in 5.16% of all CDKN2A affected cancer patients. Changes in this position may inactivate both CDKN2A gene products, i.e., p16INK4a and p14ARF , leading to loss of cell cycle control via both pRB and p53 inactivation [46]. Cancers 2022, 14, 664 9 of 32 Factors upstream of p53 are also affected and, along with the ATM kinase, play a vital role in the activation of p53 in response to DNA damage [48–54]. In our dataset, non-sense mutations leading to premature truncated forms of the ATM protein product represented more than one third of all ATM mutated cases, with R250* being the main representative. In these cases, the final gene product loses its functionality as a main DNA damage sen- sor, either partially or completely, thus increasing the vulnerability of the cell to malignant transformation [55]. Our analysis has also revealed that R337C/H are the most common cancer-related missense mutations in the ATM gene, accounting together for 7.94% of all ATM variant carriers. Although these mutations have been documented in cancer patients [56,57], to the best of our knowledge their functional impact has not been elucidated yet [58]. As expected, the dynamic presence of these genes on the mutational cancer map, has made the p53 pathway—and especially the TP53 component—an attractive therapeutic target. Among a plethora of p53-targeting strategies, the most promising fall into one of the following categories: (i) restoring the function of p53 protein or (ii) impeding the interaction between p53 and its main negative regulator, the MDM2 E3 ubiquitin ligase [35,59,60]. In this context, eprene- tapopt (APR-246), a mutant-p53 conformation resetting agent, is probably the most promising compound [61] and the only therapy of this category that is currently being tested in a phase III clinical trial (NCT03745716); on the other hand, a phase III trial of idasanutlin (NCT02545283), another emerging MDM2 inhibitor, was recently terminated due to low efficacy. The results of such clinical trials, as well as the efforts to improve the properties of the relevant compounds are highly anticipated. Apart from p53, there are four FDA approved anticancer drugs targeting CDKN2A signaling: abemaciclib, palbociclib, ribociclib and trilaciclib [62–65]. All these ther- apeutic agents act as CDK4/6 inhibitors, aiming to restore the inactivated CDKN2A [66,67]. However, it has been noted that p16INK4a loss does not necessarily predict response to CDK4/6 inhibitors [68–72]. The rationale behind ATM deficient-related therapeutic approaches however, is to cause synthetic lethality. There is evidence that this is feasible by further weakening DNA repair mechanisms via administration of appropriate inhibitors, mainly PARP and ATR in- hibitors, either alone or in combination [73–75]. Ongoing clinical trials will validate the potential of preliminary preclinical trial results and their translation into clinical practice. 4. The RTK-RAS Pathway RTK-RAS is probably the most thoroughly studied cancer-related signaling pathway. Its involvement in a multitude of crucial physiological processes, such as cell growth, proliferation, differentiation, angiogenesis, integrin signaling and cell migration [76–78], among many others, makes it clear that deregulation of this pathway can facilitate both tumor initiation and tumor progression. Indeed, our analysis showed that in 12 of 36 cancer types and subtypes examined, more than 30% of patients carried driver mutations in RTK-RAS pathway genes, with this percentage rising above 80% in papillary thyroid cancer, cutaneous melanoma and mucinous adenocarcinoma of the colon and rectum. On the other hand, as with the p53 pathway, no uveal melanoma patient was found to be affected (Figure 3). The predominantly mutated genes involved in this pathway, i.e., KRAS, BRAF and NF1, were found mutated in 26.05%, 17.06% and 13.06% of RTK-RAS perturbed cases respectively, while additional mutations in all cancer-related receptor tyrosine kinase-encoding genes represented 33.2% of all mutations. In descending order of mutational frequency, these were as follows: EGFR, ERBB2, FGFR3, FLT3, FGFR2, ERBB3, RET, KIT, MET, ERBB4, PDGFRA, ALK, FGFR1, NTRK3, NTRK1, ROS1, NTRK2, IGF1R and FGFR4. In our cohort, we ascertained that KRAS is almost exclusively mutated (missense muta- tions) on the G12, G13, Q61 and A146 residues, corresponding to more than 95% of all cases (75.41%, 11.68%, 5.84% and 3.67%, respectively). Mutants of codon 12, 13 and 61 decrease the GTP-hydrolysis rate, with mutants of codon 12 and 16 also being capable of increasing the rate of GDP-exchange [79,80], while mutants of codon 146 act mainly through the second mechanism [81,82]. Both mechanisms lead to increased levels of the activated GTP-bound form of the KRAS protein, resulting in uncontrolled mitogenic processes via a constitutively active signal transduction [80,83]. Cancers 2022, 14, 664 10 of 32 V600 is the most prevalent mutated codon of the BRAF gene, occurring in 81.74% of all BRAF mutated primary tumors in our dataset, while rearrangement of BRAF with a variety of genes seemed to occur in only 4.36% of these samples. In the majority of cases where a V600 variant exists, the valine residue is substituted by glutamic acid (V600E), enhancing the serine/threonine kinase activity of BRAF, thus leading to the abrogation of extracellular signals, promoting cell growth and proliferation [84–86]. In contrast to BRAF, there is no hotspot position for the NF1 gene. The most common somatic mutation of NF1, namely R2450*, barely exceeds 3% of all identified variants in our cohort. In addition, our analysis showed that nonsense mutations, frameshift deletions and splice-site variants are the most frequent mutation types for this gene in cancer, accounting for 39.91%, 20.83% and 15.79% of all identified variants, respectively. Regardless of the mu- tation type, in the majority of NF1-affected cases, mutations lead to a loss of neurofibromin GTPase-activating function, resulting in sustainably high GTP-bound levels of RAS proteins and thereby in a continuous tumor-promoting signaling process via RTK-RAS and PI3K/AKT pathway hyperactivation [87–90]. Regarding the development of targeted anti-cancer therapies, RTK-RAS is the most ex- tensively utilized signaling pathway. Indicatively, 64 targeted therapies have already been approved by the FDA, targeting 18 out of the 37 genes of this pathway (Table 1) [91]. For many years the KRAS gene was considered untargetable [92–95]. A milestone study in 2021, lead- ing to the discovery of the first KRAS-targeted therapy using sotorasib, an eclectic KRASG12C inhibitor, was approved for adult NSCLC patients carrying this variant who had previously been treated with at least one systemic therapy [96]. Another selective KRASG12C inhibitor, adagrasib, owing to its tolerability and clinical effectiveness, was granted a Breakthrough Ther- apy Designation by the FDA and its approval is expected soon [97]. With several more clinical trials underway e.g., JDQ-443/NCT04699188, mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA/NCT03608631 and anti-KRAS G12V mTCR PBL/NCT03190941), a new era seems to be emerging for cancer treatment. Furthermore, over the last ten years, three selective BRAFV600E inhibitors have been approved by the FDA: vemurafenib, dabrafenib and encorafenib [98–100]. These therapeutic agents, especially in combination with MEK inhibitors cobimetinib, trametinib and binimetinib respectively, have provided substantial progress-free survival (PFS) and overall survival (OS) benefit to melanoma, non-small cell lung cancer and thyroid cancer patients harboring BRAFV600E. Notably, dabrafenib and encorafenib target both BRAF and RAF1, both of which belong to the RAF family, but constitute different genes. There- fore and in line with the “Personalized Cancer Therapy” knowledge base for precision oncology (https://pct.mdanderson.org/#/home/BRAF?section=Drugs (accessed on 19 January 2022)), these genes have not been colored in blue in Table 1. Table 1. FDA approved drugs targeting the signaling of 18 cancer-related genes of the RTK-RAS pathway. Drugs that specifically target only the corresponding gene are shown in blue color. Drugs granted with a Breakthrough Therapy Designation but not yet approved by the FDA, are not included in this table. Gene Signaling Drugs Bosutinib, Brigatinib, Dasatinib, Ibrutinib, Imatinib, Niotinib, Pazopanib, Ponatinib, Regorafenib, Sunitinib, ABL1 Tivozanib, Vandetanib ALK Alectinib, Brigatinib, Ceritinib, Crizotinib, Entrectinib, Gilteritinib, Lorlatinib, Sunitinib Binimetinib, Cobimetinib, Dabrafenib, Dasatinib, Encorafenib, Regorafenib, Sorafenib, BRAF Trametinib, Vemurafenib Afatinib, Brigatinib, Ceritinib, Cetuximab, Dacomitinib, Erlotinib, Gefitinib, Ibrutinib, Lapatinib, Lorlatinib, EGFR Mobocertinib, Necitumumab, Neratinib, Osimertinib, Panitumumab, Vandetanib. Afatinib, Dacomitinib, Everolimus, Gefitinib, Ibrutinib, Lapatinib, Margetuximab, Metformin, Mobocertinib, ERBB2 Nelfinavir, Neratinib, Pertuzumab, Sirolimus, Temsirolimus, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Tucatinib Cancers 2022, 14, 664 11 of 32 Table 1. Cont. Gene Signaling Drugs Brigatinib, Dasatinib, Erdafitinib, Infigratinib, Lenvatinib, Nintedanib, Pazopanib, Ponatinib, Regorafenib, FGFR1 Sorafenib, Sunitinib, Tivozanib, Vandetanib Brigatinib, Ceritinib, Erdafitinib, Infigratinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, FGFR2 Sunitinib, Vandetanib Brigatinib, Cabozatinib, Ceritinib, Fedratinib, Gilteritinib, Ibrutinib, Midostaurin, Nintedanib, Pexidartinib, FLT3 Sorafenib, Sunitinib, Vandetanib Axitinib, Cabozatinib, Dasatinib, Fedratinib, Imatinib, Infigratinib, Lenvatinib, Midostaurin, Nilotinib, KIT Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Sorafenib, Sunitinib, Tivozanib KRAS Binimetinib, Cobimetinib, Sotorasib, Trametinib MET Cabozatinib, Capmatinib, Crizotinib, Tepotinib, Tivozanib NRAS Binimetinib, Cobimetinib, Trametinib NTRK1 Cabozatinib, Crizotinib, Entrectinib, Larotrectinib, Lorlatinib, Regorafenib, Sorafenib, Sunitinib NTRK2 Cabozatinib, Entrectinib, Larotrectinib, Lorlatinib, Sorafenib, Sunitinib Axitinib, Dasatinib, Ibrutinib, Imatinib, Lenvatinib, Midostaurin, Nilotinib, Nintedanib, Olaratumab, PDGFRA Pazopanib, Ponatinib, Regorafenib, Sorafenib, Sunitinib, Tivozanib PTPN11 Binimetinib, Cobimetinib, Trametinib Alectinib, Brigatinib, Cabozatinib, Ceritinib, Fedratinib, Ibrutinib, Lenvatinib, Pazopanib, Ponatinib, RET Pralsetinib, Regorafenib, Selpercatinib, Sorafenib, Sunitinib, Vandetanib ROS1 Brigatinib, Cabozatinib, Ceritinib, Crizotinib, Entrectinib, Lorlatinib 5. Lipid Metabolism Both lipid synthesis and catabolism are essential for the maintenance of membrane functionality, protein trafficking, immune cell responses, signaling, as well as coverage of metabolic demands, such as energy production and storage [101–105]. It has been shown that cancer cells manage to retain a high proliferative potential, through various metabolic modifications [13,106,107]. According to our analysis, more than 40% of patients of one in three cancer types/subtypes are characterized by driver mutations in genes involved in lipid metabolism. In uterine endometrioid carcinoma, astrocytoma, oligodendroglioma and oligoastrocytoma this proportion reached or exceeded 80%, while, as with the two pathways discussed above, no primary uveal melanoma tumor of our dataset was affected (Figure 3). At the gene level, PIK3CA, PTEN and IDH1 occupy the first places in the mutagenicity ranking, as they were found altered in 45.21%, 27.56% and 16.93% of the patients, respectively. Over 95% of PIK3CA somatic alterations in cancer are missense mutations, half of which include three substitutions: E545K, H1047R and E542K. These substitutions exert a gain-of-function effect on the PI3K protein via two different mechanisms. Amino acid (aa) residues E545 and E542 are located in the helical domain of p110alpha protein and their substitution by a lysine residue attenuates the inhibitory interaction between the catalytic subunit (p110alpha) and the nSH2 domain of the regulatory subunit (p85alpha) of the PI3K protein, promoting the continuous activation of PI3K [108,109]. A constitutive PI3K activation is also the result of the kinase domain variant H1047R, but in this case, p110alpha abolishes its C-terminal tail self-inhibitory capacity [110]. Both mechanisms lead to a strong activation of PI3K down- stream effectors, such as the AKT and P70S6K proteins, which mediate protein synthesis, cell growth, cell proliferation, angiogenesis, survival, and thus contribute to tumorigenic transformation [111–114]. At the same time, hyper-activated PI3K/AKT signaling induces the expression of genes involved in fatty acid anabolism, a process that generates the essential building blocks for the synthesis of new cells [115,116]. PTEN alterations show greater variety than PIK3CA alterations, with missense mutations, frameshift insertion-deletions (indels) and nonsense mutations representing 91% of all carriers. The most prevalent mutations involve R130, R233 and T319 aa residues and are found in 17.5%, 5% and 4.74% of all affected patients, respectively. In the majority of cases, arginine in position 130 is either substituted by a glutamine or a glycine residue, or, as in the cases of R233 and T319, the codon that is responsible for encoding it, is converted to a stop codon. Whereas truncating mutations such as R130*, R233* and T319* lead to an unstable, non- Cancers 2022, 14, 664 12 of 32 functional protein product [117–119], R130Q and R130G variants generate stable proteins, which, however, lack phosphatase activity [118,120]. Absence or non-functionality of the PTEN protein prevents PIP3 dephosphorylation, which in turn accumulates and recruits PI3K signaling effectors, such as AKT and PDK1 [121]. Furthermore, it was recently shown that PTENR130Q mutants tend to accumulate at the cell periphery where they form leading edges that increase tumor invasiveness and further activate the PI3K/AKT signaling axis [122]. A very impressive paradigm of a predominant mutational hotspot is represented by the IDH1 gene. Of the 467 somatic driver mutations that we identified in an equal number of cancer patients, 466 carried an R132 replacement, with histidine being the most frequent substitute (388/466 cases); cysteine, glycine, serine and leucine substitutions occurred in 50, 16, 11 and one patients, respectively. These variants, which are mapped in the catalytic pocket of the enzyme, make isocitrate dehydrogenase-1 convert the normal final product of its catalytic activity, alpha-ketoglutarate (aKG), into R(−)-2-hydroxyglutarate (2HG), with concomitant NADPH consumption [123,124]. The following 2HG-mediated inhibition of aKG-dependent deoxygenases, such as TET2 and JMJD2A/C, promotes global gene expression changes, which along with the redox stress arising from the declined NADPH levels, reflect the tumorigenic impact of these mutations [124–127]. Likewise, even though the decreased levels of two lipo- genesis components, NADPH and aKG [128] would be expected to abrogate lipid synthesis, certain lipid precursors, such as glycerol-phosphates and glycerophosphocholine, are present in elevated quantities; on the other hand, other lipid precursors, as for example myo-inositol phosphate, are present in reduced levels, compared to unaffected tumors, suggesting that cancer cells harboring IDH1 variants, alter their phospholipid expression profile, probably in a tumor-assisting manner [129–131]. As made clear from the above, signaling changes involving lipid metabolism regula- tors perturb a wide spectrum of cellular processes and contribute to cancer development. This observation has led to the development of therapies that mitigate these changes. Cur- rently, there are eleven clinically available therapies that target the signaling of four out of the 24 lipid metabolism-related genes found mutated in our dataset (Table 2) [91]. As our analysis suggests, when lipid metabolism is deregulated on account of a genetic change, this alteration invariably affects one of its aforementioned PI3K/AKT signaling-mediating regulators. Hence, inhibition of the PI3K/AKT signaling axis is suggested to be the main goal of personalized medicine for the treatment of tumors bearing such alterations. When PI3K catalytic subunit inhibitors, both isoform-specific, such as alpelisib, and pan-isoform, such as copanlisib and duvelisib, as well as selective MTOR inhibitors, including everolimus and temsirolimus, are employed, they seem to offer a significant PFS—or even OS—benefit to patients with a variety of blood or solid malignancies [132–136]. In addition, ivosidenib, an inhibitor of IDH1R132 mutants, has been approved by the FDA, for the treatment of acute myeloid leukemia (AML) patients harboring these variants [137], while its effective- ness in other IDH1-deficient cancer types is currently being tested in several ongoing clin- ical trials (e.g., advanced and metastatic cholangiocarcinoma/NCT02989857, chondrosar- coma/NCT04278781, cholangiocarcinoma—chondrosarcoma—glioma—other advanced solid tumors/NCT02073994, recurrent ependymoma—recurrent ewing sarcoma—recurrent hepato- blastoma/NCT04195555, etc.). Table 2. FDA approved drugs targeting the signaling of four cancer-related genes of the lipid metabolism pathway. Drugs that specifically target only the corresponding gene are shown in blue color. Gene Signaling Drugs IDH1 Ivositenib PIK3CA Alpelisib, Copanlisib, Duvelisib, Everolimus, Metformin, Midostaurin, Sirolimus, Temsirolimus PIK3R1 Alpelisib, Copanlisib, Duvelisib, Everolimus, Idelalisib, Midostaurin, Sirolimus, Temsirolimus, Umbralisib PTEN Alpelisib, Copanlisib, Duvelisib, Everolimus, Metformin, Midostaurin, Sirolimus, Temsirolimus Cancers 2022, 14, 664 13 of 32 6. The PI3K/AKT Pathway The impact of the PI3K/AKT signaling network on diverse cellular functions is well established. Many of these, including cell growth and proliferation, survival, motility, cel- lular metabolism, immune system functions and angiogenesis, are tightly intertwined with cancer development and progression and as a result a lot of research has been dedicated to unraveling the deregulation mechanisms of this pathway in cancer [138–141]. In 26 of the 36 cancer types of our dataset, more than 10% of patients carried at least one driver mutation in genes involved in this pathway. Uterine malignancies showed the highest mutational rates with 93.3% of uterine endometrioid carcinoma patients being affected, while the corresponding proportion of the remaining uterine tumors analyzed exceeded 60%. On the other hand, less than 5% of serous ovarian cancer, papillary thyroid cancer, pheochromocytoma, uveal melanoma and acute myeloid leukemia patients appeared to bear such changes (Figure 3). Among all PI3K/AKT-deregulated tumors examined, 53.75% harbored driver mutations in PIK3CA, 32.76% in PTEN and 12.93% in PIK3R1, with the rest of the genes in this pathway being altered in less than 6% of the tumors each. Interestingly, simultaneous mutations in at least two, or in certain cases in all of the above mentioned top mutated genes, were present in 16.34% of these patients. As driver mutations and therapeu- tic applications regarding PIK3CA and PTEN genes were discussed earlier in this report, we will now focus on the PIK3R1 gene. Somatic mutations in PIK3R1 exhibit a highly scattered pattern. The absence of predominant hotspots is reflected by the mutational rates of the most prevalent genetic changes of this gene; 6.67% for R348*, 5.67% for X582_splice and 4% for G376R. R348* is a truncating but gain-of-function mutation that exerts its tumorigenic impact in both a PI3K/AKT-dependent and a PI3K/AKT-independent manner. In addition to activating PI3K/AKT signaling, p85alpha mutants are localized into the nucleus and promote the activation of ERK and JNK kinases, thereby inhibiting FASL-mediated apopto- sis and inducing cell survival, growth, proliferation and invasion [142,143]. Even though X582 splice alteration has been previously identified and considered as pathogenic [144], its exact functional consequences have not been elucidated yet. Finally, the nSH2 domain- located G376R substitution acts in the same way as the previously discussed E545 and E542 substitutions of the p110alpha protein, thus attenuating the inhibitory interaction between the regulatory and the catalytic subunit of the PI3K complex and enhancing the PI3K/AKT signaling [145,146]. Overall, the PI3K/AKT signaling-promoting behavior of p85alpha mutants, places PIK3R1-targeting in the same therapeutic context as the other major effectors of this pathway, PIK3CA and PTEN. As shown in Table 2, the available agents targeting the signaling of these genes are essentially the same. In addition to PI3K and MTOR in- hibitors, significant efforts are being made to develop AKT inhibitors [147,148]. Most of the ongoing clinical trial test agents exert a pan-AKT (AKT1, AKT2 and AKT3) inhi- bition. Of those, capivasertib and ipatasertib have demonstrated the most encouraging results and are now tested in several phase III trials mainly regarding breast and prostate cancer patients [149] (NCT03997123/NCT04493853/NCT04862663/NCT04305496 and NCT03072238/NCT03337724/NCT04060862/NCT04650581/NCT04177108, respectively). 7. Ubiquitination and Acetylation Pathways Ubiquitination is a reversible modification that leads either to protein degradation or to the regulation of protein–protein interactions. It is essential for the appropriate execution of various cellular events, namely inflammation, translation, endocytosis, DNA damage response (DDR), protein trafficking, differentiation and signal transduction [150–154]. Thus, deregulation of the ubiquitin pathway can lead to cancer initiation and/or progression. Mutations in genes encoding components or regulators of the ubiquitination machinery are not uncommon in cancer samples. Our analysis demonstrates that such mutations are present in more than 10% of patients, in two out of three cancer types (24/36). The highest rates are shown in uterine carcinosarcoma, mucinous adenocarcinoma of the colon and rectum, uterine endometrioid carcinoma and breast invasive lobular carcinoma, Cancers 2022, 14, 664 14 of 32 ranging from ~42% to ~57%. Contrariwise, oligodendroglioma, papillary thyroid cancer, leiomyosarcoma, uveal melanoma and pheochromocytoma, exhibited the lowest rates with less than 3% of the patients being affected (Figure 3). At the gene level, the most frequently mutated genes, FBXW7 (or FBW7), EP300 and CREBBP (or CBP) were detected in 19.6%, 10.72% and 9.88%, respectively, of ubiquitination/deubiquitination-deficient tumors, while the mutational rate of nine more genes ranged between ~5% and ~9%. In descending order of mutational frequency, these are as follows: KMT2B, RNF43, VHL, MAP3K1, KMT2A, SPOP, BAP1, KEAP1 and BRCA1. Three arginine residues of the FBW7 ubiquitin ligase—R465, R505 and R479—represent 43.59% of all FBW7 somatic driver mutations in primary tumor samples. These positions are located into the WD40 domain, which constitutes the substrate-binding site of the SCF complex (a type of E3 ligase), which is responsible for the ubiquitin-labeling and the subsequent proteasome-mediated degradation of its protein effectors [155,156]. These mutations induce changes in the WD40 domain, altering the interaction potential of FBW7, probably via both hydrophobic and electrostatic interactions, as well as by limiting the contact surface because of the shorter substitute sidechains (mainly cysteine, histidine, glycine and glutamine) [157]. Given that several FBW7 interactors act as regulators of cell growth, apoptosis and proliferation [158–163]; prevention of their degradation may result in tumorigenesis. Even though the EP300 gene is usually altered by nonsense mutations, the most re- current mutations fall into three other categories. The D1399N substitution is the most prevalent somatic mutation of this gene, accounting for 7.29% of EP300-mutated primary tu- mors in our working dataset. Missense mutations in this position were shown to change the conformation of the p300 protein histone acetyltransferase (HAT) domain, leading to abol- ishment of its autoacetylation activity, which is essential for appropriate function [164,165]. The subsequent inability of p300 to stimulate other tumor suppressors in the nucleus, such as RB1, BRCA1, p53 and AP-2alpha [166–170], paves the way for the predominance of its spatial distinct, cytoplasmic ubiquitin ligase activity, which targets p53 for degra- dation [171–173]. These changes, together with the reduced global levels of histone H3 acetylation [174], contribute to the tumorigenic impact of this genetic alteration. The sec- ond and third most prevalent mutations of the EP300 gene are the frameshift deletion M1470Cfs*26 and the splice site variant X1429 splice, and were each identified in 2.6% of EP300-affected patients. However, their functional impact is not clear. Another gene with intrinsic histone acetyltransferase activity, sharing high similarity to EP300, is the CREBBP gene. Missense mutations involving the R1446 are the most recurrent somatic mutations of CREBBP, followed by frameshift indels involving I1084 and substitutions of D1435, accounting for 7.91%, 5.65% and 2.82% of CREBBP-affected primary tumors, respectively. Both R1446 and D1435 are located in the HAT domain, which is responsible for the catalytic activity of the CBP transcriptional coactivator. Substitution of these aa residues, reduces the acetyl-CoA binding affinity of CBP, thereby impairing its acetyltrans- ferase activity [175–177]. Consequently, CBP can neither activate p53 tumor suppressor nor inactivate BCL6 proto-oncoprotein. Furthermore, as with its structurally and func- tionally related p300 protein, CBP also exhibits an E4 ubiquitin ligase activity targeting p53 for degradation in the cytoplasm [171]. These observations, in conjunction with the arisen extended transcriptional changes, dictate a tumor promoting effect for these muta- tions [175,178]. The functional impact of frameshift deletion I1084Sfs*15, which is found in 4.52% of CREBBP-altered samples thus far remains obscure. Proteins involved in either the attachment or the removal of ubiquitin moieties are barely exploited in clinical practice nowadays [179]. An exception to this rule is provided by thalidomide analogues lenalidomide and pomalidomide, which have been approved for the treatment of various blood malignancies and exhibit anti-tumor activities by altering the specificity of cereblon, which constitutes the substrate recognition component of the CRL4 E3 ubiquitin ligase complex [180,181]. Nonetheless, targeting of the proteolytic machinery is primarily oriented to proteasome inhibition, with three inhibitors—bortezomib, carfilzomib Cancers 2022, 14, 664 15 of 32 and ixazomib—already approved for the treatment of multiple myeloma and mantle cell lymphoma [182], while other agents, such as delanzomib (CEP-18770) and marizomib or salinosporamide A (NPI-0052) [183] are currently being tested in clinical trials as potential treatment options for solid tumors (NCT00572637 and NCT03345095, respectively). 8. The WNT/b Catenin Pathway The WNT/b catenin pathway is one of the best-studied signaling cascades in cancer development, known to be implicated in several cancer-related cellular functions, such as cell proliferation, stem cell maintenance, differentiation, cell–cell adhesion, morphogenetic processes, migration, angiogenesis and immune evasion [184–188]. Mutations in WNT/b catenin components are very common in cancer patients. Our analysis revealed that carcinogenic mutational occurrences in genes of this pathway are limited compared to the pathways discussed so far. Specifically, the proportion of patients with at least one driver mutation in this pathway exceeded 10% in only nine of the thirty-six cancer types examined here. Intestinal malignancies ranked highest in terms of mutational landscape with at least 80% of colon adenocarcinoma, rectal adenocarcinoma and mucinous adenocarcinoma of the colon and rectum patients harboring driver alterations. On the other hand, no such mutations were found in uveal melanoma or leiomyosarcoma patients (Figure 3). Among WNT/b catenin effectors, the APC, CTNNB1 and RNF43 genes were found mutated in 48.59%, 26.41% and 14.94% of the affected samples, respectively, while four other genes (in descending order of mutational frequency: AMER1, AXIN1, TCF7L2 and AXIN2) exhibited a driver mutational rate between ~5% and ~8%. The most frequent mutations are nonsense mutations in the APC tumor suppressor, present in 40.6% of patients. Conversion of arginine-encoding codons into stop codons pre- dominantly takes place at positions 1450, 876 and 1114 of the APC protein (8.51%, 4.84% and 4.64% respectively). R1450 is located into the so-called mutation cluster region (MCR) [189]. Truncation of the APC protein in this position leads to loss of all axin- and most b catenin- binding sites, therefore abrogating the ability of APC to negatively regulate b catenin via the formation of the destruction complex AXIN-APC-CK1alpha-GSK3beta [190–193]. Similarly, two other truncations, namely the R1114* and R876* mutants, also lose the axin- and most b catenin-binding sites [194,195]. In all three cases, the subsequent b catenin accu- mulation and nuclear entry permits activation of the TCF/LEF1 transcriptional complex, thereby promoting cellular proliferation and tumorigenesis [192]. Somatic mutations in the CTNNB1 (catenin-beta 1) gene, which is involved in the reg- ulation of cell adhesion and gene transcription, are almost exclusively missense mutations. In particular, aa substitutions at six specific positions (32, 33, 34, 37, 41 and 45) represent more than 85% of all affected patients in our dataset. Among them, S33, S37 and D32 replacements were the most prevalent, affecting 18.51%, 17.44% and 16.01% of all cases, respectively. The protein region between D32 and S45 participates in the phosphorylation of b catenin from CK1alpha and GSK3beta (components of its destruction complex), as well as in the interaction of phosphorylated b catenin with its E3 ligase substrate recog- nition component, FBW1 [196,197]. Consequently, mutations in these protein sites exert similar signaling implications to the ones exerted by APC, as b catenin escapes proteasomal degradation and confers an increased proliferative potential to the cell [197–201]. Another gene found mutated in cancer patients is the RNF43 (Ring Finger Protein 43), a downstream target gene of Wnt/b catenin signaling. Almost seventy-three percent of RNF43-mutated primary tumors carry a frameshift deletion in this gene, while the second most frequent alteration type is a non-sense mutation (~17%). By far the most common alteration of the RNF43 protein is G659Vfs*41, being present in approximately 60% of all RNF43-mutated tumors. Interestingly, despite its recurrent presence in cancer samples, this frameshift deletion leaves protein function intact, with the relevant RNF43-mutant being able to exert its E3 ubiquitin ligase activity [202]; this results in the tagging of FZD family (frizzled transmembrane proteins) WNT receptors for proteasomal degradation and in the inactivation of WNT/b catenin signaling [203,204]. The second and third Cancers 2022, 14, 664 16 of 32 most frequent somatic mutations of the RNF43 protein are R519* and R145*, affecting only 2.52% and 1.89% of all carriers, respectively. Both of these aberrations lead to a truncated protein with a WNT signaling-enhancing role, however the exact mechanism differs depending on the truncation position. The catalytic RING domain of RNF43 lies among P270 and I316 [202,205], and as such the R519* mutant retains its E3 ubiquitin ligase activity. Nonetheless, it simultaneously gains the ability to snare CK1alpha at the plasma membrane, thus assisting b catenin to escape degradation [206]. On the other hand, R145* variants lack this catalytic activity and are therefore expected to abort their FZD degradation and b catenin destabilization role [202]. Significant efforts have been made to therapeutically target the WNT/b catenin net- work, mostly for the development of small molecule stabilizers of the b catenin destruction complex components or destabilizers of the b catenin-TCF/LEF interaction, but also for the development of antibodies and regulatory peptides that directly or indirectly affect—mostly inhibit—WNT or FZD proteins [192,207,208]. Four such constructs have exhibited the most encouraging results and their efficacy is currently evaluated in phase II clinical trials of both solid and blood cancer patients. In this context, WNT974 (NCT02278133)—a porcupine inhibitor that impedes WNT secretion and activity, Foxy-5 (NCT03883802)—a WNT5a mimetic, PRI-724 (NCT01606579)—an antagonist of the b catenin coactivator CBP, and DKN-01 (NCT03395080)—a monoclonal antibody that neutralizes the activity of WNT/b catenin axis inhibitor DKK1, are now in the spotlight of WNT pathway targeting. 9. The Notch Pathway Notch is a cancer-related signaling pathway well-known for its involvement in a variety of developmental processes, as well as cellular differentiation, proliferation, stem cell maintenance, angiogenesis, EMT, inflammation and apoptosis [209–211]. Mutations in the Notch pathway, were found in at least one in ten patients in fifteen out of thirty-six assessed cancer types. Uterine carcinosarcoma exhibited the highest driver mutational rate (40.35%), followed by mucinous adenocarcinoma of the colon and rectum (33.93%) and bladder urothelial carcinoma (29.02%), while other gynecological and upper digestive tract malignancies, were also highly affected. On the other hand, none of the patients with pheochromocytoma and no more than 2% of patients with leiomyosarcoma, uveal melanoma and papillary thyroid cancer carried such mutations (Figure 3). At the gene level, the most frequently mutated components or regulators of the Notch pathway appeared to be identical to the above discussed ubiquitination pathways; FBXW7, EP300 and CREBBP were found altered in 33.65%, 18.41% and 16.97% of Notch-impaired tumors, respectively, while somatic driver events in each of the SPEN, NCOR1 and NOTCH1 genes, were detected in ~12% of cases. Upon activation of the NOTCH receptors by their ligands (e.g., delta-like protein 1, protein jagged-1 etc), the NOTCH-intracellular domain (NICD) is released and transferred into the nucleus where it acts as a transcription regulator. NICD is one of the FBW7 substrates [159] and mutations within the FBW7 WD40 domain have been reported to impede this interplay, therefore leading to NICD accumulation and enhanced Notch signaling, which may lead to a tumorigenic outcome [157,212,213]. Furthermore, despite the previously reported p300 requirement for NICD transcriptional activity [214,215], it was recently demonstrated that loss-of-function mutations in either the EP300 or CREBBP gene can also activate the Notch axis, due to the subsequent low histone acetylation levels of the FBXW7 promoter [216], suggesting the implication of additional transcriptional NICD co-activators. So far, no targeted therapies for Notch signaling regulation have entered the clinical practice. However, remarkable efforts have been made to overcome the obstacles asso- ciated with Notch pathway signaling, given the highly context-specific behavior of this signaling axis in cancer [217]. To this end, diverse strategies have been utilized, such as the targeting of NOTCH biosynthesis enzymes, receptor-ligand interplay, NOTCH cleavage- performing effectors or NICD-containing transcriptional complexes assemblage [217–219]. The most encouraging results come from the development of inhibitors against gamma- Cancers 2022, 14, 664 17 of 32 secretase—which is responsible for the final NICD-releasing NOTCH cleavage—and delta- like protein 3, a NOTCH ligand, with some of the relevant cancer-related clinical trials being in advanced stages. Specifically, the efficacy of gamma-secretase inhibitors (GSIs) nirogacestat/PF-03084014 (NCT03785964) and MK0752 (NCT00756717) is currently eval- uated in phase III trials in adults with desmoid tumor and in early stage breast cancer patients in combination with tamoxifen respectively, while the tesirine conjugated anti- delta-like protein 3 mAb rovalpituzumab (Rova-T) (NCT03061812) is being tested in a phase III clinical trial in small-cell lung cancer (SCLC) patients with disease progression following platinum-based chemotherapy and overexpressing delta-like protein 3. 10. The Cell Cycle Pathway The cell cycle is a set of fine-tuned, strictly inspected processes which mediate between the end of two consecutive cell divisions and are responsible for the apt preparation of the cell towards a complete, equal and accurate cell material distribution between daughter cells. Consequently, functional disruption of key cell cycle mediators can provoke loss of proliferation control, as well as a disturbance of the genomic integrity, both fundamental features of cancer [220,221]. Driver somatic mutations of crucial cell cycle components are present in more than 10% of patients in 25% of the cancer types studied. For some malignancies the occurrence rate exceeds even 20%, with bladder urothelial carcinoma, head and neck squamous cell carcinoma and lung squamous cell carcinoma patients being affected in 30.24%, 22.52% and 20.04% of cases, respectively. At the same time, no such alterations were found in patients with renal clear cell carcinoma, acute myeloid leukemia, uveal melanoma or pheochromocytoma (Figure 3). Indisputably, the retinoblastoma tumor suppressor RB1 and the previously discussed CDKN2A are the most commonly mutated cell cycle genes, identified in 44.43% and 41.11% of all cell cycle-perturbed primary tumors, respectively; despite ranking third in mutational frequency, the CDKN1A gene was found mutated in 6.76% of assessed tumors. Somatic mutations were highly dispersed along the RB1 gene, with 203 of the 928 aa-encoding codons found to be implicated in a driver event in our dataset. Even though more than 40% of these genomic changes were non-sense mutations, the most recurrent appears to be the splice site mutation X405_splice, which nevertheless accounts for only ~3% of RB1-mutated tumors. Among the nonsense alterations, R320* and R552* were the most prevalent, being present in 2.09% of cases each. All three of these alterations constitute inactivating muta- tions that impair both RB1 functional domains (A- and B-boxes) [222–225]. Such alterations abrogate one of the cell cycle restriction points, as a non-functional or absent RB1 protein permits E2F-mediated G1/S transition, thereby enhancing the cell’s proliferative potential and contributing to tumorigenesis or tumor progression [226,227]. On the other hand, somatic driver genomic alterations in CDKN1A are extremely rare, as only 51 out of 10,066 (~0.5%) assessed primary tumor samples appeared to be affected, with the majority de- tected in bladder urothelial carcinoma (39/51) and hepatocellular carcinoma (7/51) patients. Frameshift indels and nonsense mutations represent the lion’s share of CDKN1A gene al- terations. Q10* and M38Nfs*10 are the most recurrent among them, accounting for 7.84% and 5.88% of p21-deficient tumors, respectively. Although experimentally uncharacterized, both mutations are expected to abrogate p21 functionality due to loss of most functional domains. Such aberrations are likely to assist tumor progression, as deficient p21 is unable to prevent cell cycle progression and DNA synthesis through cyclin-CDK complexes or PCNA inhibition [228–232], while in the case of M38Nfs*10 frameshift insertion, the intact 33 NH2-terminal aa residues, where procaspase-3 binding domain is located, might further facilitate tumor progression due to sustenance of p21 anti-apoptotic activity [233,234]. Thus far, therapeutic targeting of the cell-cycle is largely based on CDK4/6 inhibi- tion [235]. Three such inhibitors, palbociclib, ribociclib and abemaciclib have already received FDA approval either as monotherapy or in combination with hormone therapies, for the treatment of advanced HR+ /HER2- breast cancer [62–64]. Recently, another CDK4/6 inhibitor, trilaciclib, was also approved for the prevention of chemotherapy-induced myelo- Cancers 2022, 14, 664 18 of 32 suppression in small cell lung cancer (SCLC) patients [65]. In parallel, many more such inhibitors are currently being tested in clinical trials for their potential to confer improved anti-tumor activity, but accompanied by less toxicity. Of these, dalpiciclib (SHR6390) is the only compound currently tested in phase III trials (NCT03966898 and NCT03927456), while many pan-CDK inhibitors are being evaluated in earlier phases of clinical development [91]. Apart from CDKs, several inhibitors of other cell-cycle components, such as CHK1, PLKs and Aurora proteins, have also entered clinical testing [236]. 11. The HDR Pathway Homology-directed DNA repair (HDR) is one of the two major mechanisms responsible for double strand breaks (DSBs) repair [237,238]. Given the detrimental impact of DSBs on genomic stability [239], malfunction of the HDR pathway may facilitate malignant transforma- tion [240]. Our analysis showed that somatic driver mutations in HDR pathway components are not rare events in cancer. In particular, 23.71% of patients with uterine endometrioid carcinoma harbored such mutations, while the relative fractions in five gastrointestinal cancer types—mucinous adenocarcinoma of the colon and rectum, stomach adenocarcinoma, diffuse type stomach adenocarcinoma, tubular stomach adenocarcinoma and colon adenocarcinoma— were 21.43%, 17.39%, 13.89%, 12.66% and 10.95%, respectively. In contrast, less than 1% of patients with papillary thyroid cancer and oligodendroglioma, and none of the oligoas- trocytoma patients carried such alterations (Figure 3). Among HDR compounds, BRCA2, BRCA1 and TP53BP1 were the most frequently affected genes, being altered in 25.17%, 14.73% and 13.01% of HDR-impaired patients, respectively; the relative mutational rates of eight additional genes (in descending order of mutational frequency: BRIP1, RAD51B, NBN, RAD50, BLM, SLX4, BARD1 and PALB2), ranged between ~5 and ~9%. Almost 41% of somatic mutations in the BRCA2 tumor suppressor are truncating mutations, most of which result in loss of multiple BRCA2 functional domains. However, the most recurrent BRCA2 protein changes are the frameshift insertion N1784Kfs*3, the frameshift deletion K1691Nfs*15 and the missense mutation R2842C, which were detected in 3.4%, 2.72% and 2.04% of all BRCA2-mutated primary tumor samples in our analysis, respectively. The R2842 substitution by a cysteine residue has been demonstrated to miti- gate HDR efficiency [241]. Although N1784Kfs*3 and K1691Nfs*15 have been previously identified [242], their exact functional consequences remain unresolved. Nevertheless, the final shortened variants lack crucial BRCA2 C-terminal domains, such as some of the RAD51-binding sites, the DNA-binding domain and their nuclear localization sequences (NLSs) [238,243], likely dictating a loss-of-function effect. A dysfunctional BRCA2 protein is incapable of efficiently recruiting RAD51 at DSB sites, thereby preventing RAD51 nucleo- protein filament formation. This hinders homology-directed invasion of damaged DNA to the intact sister chromatid [244–246], thereby contributing to genome instability, one of the hallmarks in cancer. Similar to BRCA2, nonsense mutations are also predominant in the BRCA1 gene (~41%). At the protein level, the most common mutations appear to be the frameshift insertion E111Gfs*3 and the nonsense mutations E720* and E572*, accounting for 3.49% and 2.33% of all BRCA1-affected tumors, respectively. Despite the previous identification of all three variants [247], their functional consequences have not been experimentally validated yet. However, the truncation sites of these mutants dictate the loss of coiled-coil domain, RAD50- and RAD51-binding domains and the two BRCT domains, while E572* and E111Gfs*3 variants are additionally expected to lack one or both BRCA1 nuclear localization sequences, respectively [248–251]. Such variants are most likely unable both to prevent 53BP1-mediated inhibition of the initial HDR step, viz., DNA end resection by MRE11-RAD50-NBS1 (MRN) complex [252], and to recruit and stabilize the RAD51 protein onto the DSB sites [251], thus resulting in HDR deficiency. Nonsense mutations and frameshift deletions account for ~80% of TP53BP1 driver somatic mutations in cancer, mainly corresponding to E737* (6.58%), N1017Mfs*20 (6.58%) and E711Nfs*12 (3.95%). All three constitute truncating mutations leading to loss of both the NLS and the four C-terminal functional domains of 53BP1 protein. It was recently demonstrated that Cancers 2022, 14, 664 19 of 32 such changes result in significant retardation of DSB repair, suggesting impairment of the 53BP1-mediated non-homologous end joining (NHEJ) repair mechanism [253]. Although 53BP1 can act as an HDR negative regulator [252,254], the predominant role of NHEJ on DSB repair, primarily during the G1 phase, when the HDR is inactive [255], renders 53BP1 deficiency a genome stability-threatening situation. Targeted therapy of HDR-deficient tumors is highly based on the synthetic lethality concept [256–258], wherein mutations in different genes can lead to cell death when they appear concurrently. In this context, BRCA1/2-deficient tumors, which lack the ability to accurately repair DSBs, can be treated with single strand break (SSB) repair inhibitors, such as inhibitors of the base excision repair-mediators PARP1/2 [259]. Four such agents, olaparib, rucaparib, niraparib and talazoparib, are clinically available for the treatment of pretreated advanced breast, ovarian and fallopian tube or primary peritoneal cancer patients harboring BRCA1/2 mutations (this restriction does not apply to niraparib), either germline or/and somatic [260–264]. Several more PARPis are in clinical development with three of them, fluzoparib (NCT03863860), pamiparib (NCT03519230) and veliparib (NCT02470585, NCT02163694 and NCT02152982), currently being tested in phase III trials. In addition to the BRCA1/2m—PARPis couple, increasing evidence demonstrates that synthetic lethality may also take place following ATR inhibition in HDR-deficient tumors carrying inactivated ATM [265–267], with active ongoing phase II clinical trials testing two such agents: berzosertib (NCT02567409, NCT03517969 and NCT02595892) and cer- alasertib (NCT03330847, NCT03328273, NCT03787680 and NCT02937818), in a variety of human cancers. 12. The Splicing Pathway Splicing is the process of exon joining following intron exclusion that takes place during the conversion of pre-mRNA to its mature translatable form. Under certain circum- stances, an aberrant splicing procedure can be oncogenic [268–271]. Our analysis revealed that somatic driver events involving splicing machinery components are not uncommon in malignancies. Thus, cancers from different anatomical regions, namely uveal melanoma, oligodendroglioma, uterine endometrioid carcinoma, lung adenocarcinoma, mucinous adenocarcinoma of the colon and rectum, and bladder urothelial carcinoma, exhibited a splicing pathway-related mutation rate of 23.75%, 18.52%, 13.92%, 10.95%, 10.71% and 10.24%, respectively. In contrast, less than 1% of patients with glioblastoma multiforme and pheochromocytoma, and none of the patients with papillary thyroid cancer or leiomyosar- coma harbored such mutations (Figure 3). At the gene level, SPEN, CDK12 and FUBP1 appeared to be the most commonly mutated genes, being identified in 20.82%, 19.89% and 17.84% of splicing-impaired tumors, respectively, whereas the corresponding proportion of four additional genes fluctuated between ~8% and ~14% (in descending order of mutational frequency: RBM10, SF3B1, DDX3X and U2AF1). The SPEN gene, which encodes for the SMRT/HDAC1-associated repressor protein (SHARP or SPEN), is mostly affected by nonsense mutations and frameshift deletions (~81% of driver events). The most recurrent protein alterations include I1052Sfs*40, A2251Qfs*102 and P2495Lfs*4 (2.68% each), however none of these has so far been functionally char- acterized. Nonetheless, the undetectable SPEN protein levels accompanying an inser- tion/truncation in position 1184 [272], point towards a loss-of-function in the I1052Sfs*40 variant. Furthermore, all three variants lack the C-terminal SPOC domain [205], which is essential for SPEN transcriptional co-repressor activity, as it mediates the interaction with SMRT/NCoR [273]. SPEN-deficient cells are not capable of hindering ER alpha oncogenic effects, thereby contributing to tumor formation [272]. However, the mechanism via which abolishment of SPEN splicing-related activity—likely a link between RNA splicing and mRNA nuclear export machines [274]—may contribute to tumorigenesis, remains unclar- ified. Another highly mutated gene involved in splicing is the cyclin-dependent kinase 12 (CDK12). Nearly 80% of patients affected by a somatic driver mutation in CDK12 gene, harbor a fusion, a frameshift deletion or a nonsense mutation. Nevertheless, the R890H Cancers 2022, 14, 664 20 of 32 substitution is the most recurrent variation (3.74%), followed by the frameshift deletion P683Qfs*70 and the CDK12-IKZF3 fusion (2.8% each). The functional consequences of these alterations have not been experimentally delineated yet. R890 is located into the kinase domain (aa residues 737–1020) [275]. Proximal aa substitutions have been shown to either prevent CDK12 interaction with its protein partner cyclin K, or to considerably decrease its kinase activity [276]. In addition, P683Qfs*70 truncation results in the elimination of almost its entire kinase domain. The inability of CDK12 to phosphorylate the C-terminal domain of RNA polymerase II, prevents it from transcriptionally-activating several target genes of the HDR pathway, as well as of other DDR components [276–278]. Furthermore, CDK12- deficiency may promote proximal alternative last exon (ALE) splicing of certain DDR genes, such as ATM, thus limiting the abundance of full-length protein products [279], and in this way impeding DNA repair processes and further contributing to genome instability and cancer development. The FUBP1 gene is another highly mutated gene involved in splicing (far upstream element-binding protein 1, FBP), which regulates MYC expression by binding to a single- stranded far-upstream element (FUSE). The most frequent FUBP1 mutations are frameshift deletions, detected in 37.5% of all carriers. The frameshift deletion S11Lfs*43 is the most fre- quently repeated somatic alteration, being present in 9.38% of patients, followed by R430C substitution (8.33%)—the only missense mutation identified in 96 FBP-mutated patients— and frameshift indels involving I301 (5.20%). All these changes have been identified by massive sequencing approaches, but are not yet characterized [280,281]. Variants harboring either S11Lfs*43 or I301-involving out-of-frame mutations, namely deletions I301Yfs*22 and I301Nfs*22 as well as insertion I301Nfs*4, lose more than 90% or at least half of their protein body respectively, which suggests a loss-of-function effect. Although known as a positive regulator of the MYC proto-oncogene [282], it is the previously reported FBP participation in a MYC-repressing complex with FIR [283] that is consistent with a tumor-promoting scenario. Additionally, it has been demonstrated that FBP loss hampers proper MDM2 splicing, giving rise to the tumorigenesis-accelerating MDM2-ALT1 splice variant [284]. Therapeutic targeting of the splicing pathway is still far from entering the clinic. How- ever, strategies have been developed towards this direction. These include three main approaches: (i) spliceosome assembly disruption through the inhibition of core spliceosome components (e.g., SF3B1) or their regulators (e.g., SRPKs and CLKs) using small molecules, (ii) control of the utilized splicing regulatory elements (exonic and intronic splicing en- hancers or silencers) or inhibition of cancer-related aberrantly expressed splicing factors by oligonucleotides, and (iii) targeting of abnormal splice isoforms [285–287]. Currently, the first strategy has come to the fore, being the only approach to include compounds under clinical evaluation. Thus, two SF3B-complex (a component of U2 snRNP) inhibitors, E7107 (NCT00459823 and NCT00499499) and H3B-8800 (NCT02841540) are currently being tested in phase I trials for their safety and anti-tumor activity, against solid and hematological malignancies, respectively. 13. Conclusive Remarks In this study, we review the most popular cancer-related signaling pathways as sorted by their somatic driver mutational rates calculated in our analyses. Several pathways can be simultaneously deregulated in a tumor. Our analysis showed that this applies to the majority of tumors. This may result either from putatively independent co-alterations of two or more genes implicated in discrete signaling pathways, or due to alterations in genes acting as nodes between multiple signaling cascades (e.g., the PIK3CA and PTEN genes in PI3K/AKT and lipid metabolism pathways). The complexity of the underlying interlinked mechanisms makes it difficult to identify a single disease-causative implicated pathway. From a conceptual point of view, genes may play distinct roles in more than one pathway and a driver mutation can be implicated in the dysregulation of several pathways. As such, the designation of one particular pathway (or a part of the associated pathways) as the ‘most highly associated to a tumor’, is supported by the mutational profiles (the Cancers 2022, 14, 664 21 of 32 combination of mutations occurring in the genes involved in each pathway). Analysis of the ten pathways with the highest mutational frequencies led to the identification of the cancer types most frequently affected, which in turn facilitated the description of the most repeatedly identified alterations/mutations in key members of these pathways and their direct or indirect consequences in the signaling process; importantly, the potential for therapeutic exploitation of these alterations is discussed, which may further highlight new targets for personalized cancer treatment opportunities. Despite the complexity that the simultaneous deregulation of multiple signaling cas- cades in many tumor types creates, the present study manages to unravel, at least to a certain extent, the remarkable diversity of mechanisms by which somatic mutations can drive cell signaling perturbance in cancer. For example, in our analysis, somatic driver mutations in key regulators of RTK-RAS, lipid metabolism and WNT/b catenin pathways, appeared to co-exist in nearly 40% of patients with mucinous adenocarcinoma of the colon and rectum. Furthermore, mutations in different regions of a single gene may deregu- late distinct signal transduction networks. Such a paradigm is represented by the R348* mutation in PIK3R1 which, in contrast to other protein region alterations that seem to suffer only PI3K/AKT axis activation as a functional consequence, it appears to addition- ally enhance MAPK signaling, making cells sensitive to MEK and JNK inhibition [142]. These observations underline the importance of patient mutational profiling for thera- peutic decision-making and provide valuable insight to the functional and mechanistic characterization of cancer-related variants. Several recurrent cancer-related variants remain uncharacterized. These involve com- ponents of crucial signaling pathways, including PI3K/AKT, ubiquitination, cell cycle and splicing. CREBBP and FUBP1 genes represent some of the most interesting cases. The cellular compartment-dependent roles of CBP either as a histone acetyltransferase or as an E4 ubiquitin ligase and their opposing effects on p53 activation [171], highlight the im- portance of investigating I1084-related frameshift effects, due to their potential therapeutic value. S11Lfs*43, R430C and the three identified I301-involving frameshift indels, together account for more than one fifth of FUBP1-affected tumors. The recent inclusion of the FUBP1 gene in the “long-tail driver” category of the less-frequently mutated genes due to its alternative splicing regulatory role in several oncogenes and tumor suppressors [288], makes it a very attractive therapeutic target. New horizons in cancer treatment may also arise from more adequately understood cancer contributors. Thus far, targeting of the ubiquitin-proteasome system (UPS) is primarily based on proteasome inhibition. However, broad use of this strategy is limited due to problems caused by the accumulated ubiquitin- labeled proteins [179]. Therefore, targeting earlier steps of the process might surmount this hurdle. Furthermore, the tumor-suppressor FBXW7, which is mutated in one fifth of ubiquitination-deficient tumors, also appears to be an appealing target, given its role in the destabilization of many proto-oncoproteins [289]. Considering the well-studied and clinically exploitable synthetic lethality concept, exploration of new DDR member couples, apart from BRCA1/2-PARPs, may also prove valuable. For example, TP53BP1 is one of the most frequently mutated members of the major DNA DSB repair pathways (HDR and NHEJ), and driver mutations in this gene are mutually exclusive to BRCA1/2 mutations in 80% of cases, thereby providing a template for extending the synthetic lethality concept to HDR-proficient tumors. The already established synthetic lethal interaction between 53BP1 and DNA polymerase theta, the key mediator of another DSB repair mechanism called theta mediated end joining (TMEJ) [290,291], is in line with this notion. Despite focusing on just one of the –omics areas, this work gives a useful overview of the current knowledge on signaling pathway deregulation in cancer. Understanding the impact of such molecular events in cell signaling could provide the basis for better exploitation of the existing targeted therapies, and also facilitate the enrichment of the current therapeutic arsenal with agents targeting frequently affected but still considered as undruggable pathways, such as the splicing pathway, thereby paving the road to more effective combinatorial therapies. Cancers 2022, 14, 664 22 of 32 Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/cancers14030664/s1, Supplementary Material S1: Code of the analysis, Supplementary Material S2: Query for searching for driver events of the genes of interest using cBioPortal Onco Query Language (OQL). Author Contributions: A.K.: bibliographic data analysis, manuscript writing and figure preparation; M.A., A.T. and R.F.: preparation of the manuscript and selection of findings; V.Z., B.V. and K.K.: review conceptualization and preparation of manuscript and figures. All authors have read and agreed to the published version of the manuscript. Funding: This study was co-funded by the European Regional Development Fund and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research–Create–Innovate (project code: T2EDK-03266, project acronym and title: “BIOKARETRA—Identification of genomic and transcriptomic prognostic bio-signatures in head and neck cancer”); and BV was also supported by the European Regional Development Fund—Project ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868) and by the Ministry of Health Development of Research Organization, MH CZ—DRO (MMCI, 00209805). Conflicts of Interest: The authors declare no conflict of interest. References 1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed] 2. Goodwin, S.; McPherson, J.D.; McCombie, W.R. Coming of age: Ten years of next-generation sequencing technologies. Nat. Rev. Genet. 2016, 17, 333–351. [CrossRef] [PubMed] 3. Carrasco-Ramiro, F.; Peiro-Pastor, R.; Aguado, B. Human genomics projects and precision medicine. Gene Ther. 2017, 24, 551–561. [CrossRef] 4. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6, 714–727. [CrossRef] [PubMed] 5. O’Connor, M.J. Targeting the DNA Damage Response in Cancer. Mol. Cell 2015, 60, 547–560. [CrossRef] [PubMed] 6. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205–214. [CrossRef] [PubMed] 7. Parui, A.L.; Bose, K. Cancer Biology and Its Treatment Modalities: A Brief Historical Perspective. In Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach; Bose, K., Chaudhari, P., Eds.; Springer: Singapore, 2019; pp. 1–11. [CrossRef] 8. Martincorena, I.; Campbell, P.J. Somatic mutation in cancer and normal cells. Science 2016, 349, 1483–1489, Erratum in Science 2016, 351, aaf5401. [CrossRef] 9. Okugawa, Y.; Grady, W.M.; Goel, A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology 2015, 149, 1204–1225.e1212. [CrossRef] 10. Sever, R.; Brugge, J.S. Signal transduction in cancer. Cold Spring Harb. Perspect. Med. 2015, 5, a006098. [CrossRef] 11. Baylin, S.B.; Jones, P.A. Epigenetic Determinants of Cancer. Cold Spring Harb. Perspect. Biol. 2016, 8. [CrossRef] 12. Feinberg, A.P.; Koldobskiy, M.A.; Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016, 17, 284–299. [CrossRef] [PubMed] 13. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed] 14. Sanchez-Vega, F.; Mina, M.; Armenia, J.; Chatila, W.K.; Luna, A.; La, K.C.; Dimitriadoy, S.; Liu, D.L.; Kantheti, H.S.; Saghafinia, S.; et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 2018, 173, 321–337.e310. [CrossRef] [PubMed] 15. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789–799. [CrossRef] [PubMed] 16. Dempke, W.C.M.; Fenchel, K.; Uciechowski, P.; Chevassut, T. Targeting Developmental Pathways: The Achilles Heel of Cancer? Oncology 2017, 93, 213–223. [CrossRef] [PubMed] 17. Pon, J.R.; Marra, M.A. Driver and passenger mutations in cancer. Annu. Rev. Pathol. 2015, 10, 25–50. [CrossRef] 18. Stratton, M.R.; Campbell, P.J.; Futreal, P.A. The cancer genome. Nature 2009, 458, 719–724. [CrossRef] 19. Johnson, A.; Zeng, J.; Bailey, A.M.; Holla, V.; Litzenburger, B.; Lara-Guerra, H.; Mills, G.B.; Mendelsohn, J.; Shaw, K.R.; Meric-Bernstam, F. The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform. Drug Discov. Today 2015, 20, 1433–1438. [CrossRef] 20. Saltz, L.B.; Meropol, N.J.; Loehrer, P.J., Sr.; Needle, M.N.; Kopit, J.; Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201–1208. [CrossRef] 21. Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crino, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368, 2385–2394. [CrossRef] Cancers 2022, 14, 664 23 of 32 22. Zhan, T.; Rindtorff, N.; Betge, J.; Ebert, M.P.; Boutros, M. CRISPR/Cas9 for cancer research and therapy. Semin. Cancer Biol. 2019, 55, 106–119. [CrossRef] [PubMed] 23. Khalaf, K.; Janowicz, K.; Dyszkiewicz-Konwinska, M.; Hutchings, G.; Dompe, C.; Moncrieff, L.; Jankowski, M.; Machnik, M.; Oleksiewicz, U.; Kocherova, I.; et al. CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials. Genes 2020, 11, 921. [CrossRef] [PubMed] 24. Ge, Z.; Leighton, J.S.; Wang, Y.; Peng, X.; Chen, Z.; Chen, H.; Sun, Y.; Yao, F.; Li, J.; Zhang, H.; et al. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep. 2018, 23, 213–226.e213. [CrossRef] [PubMed] 25. Knijnenburg, T.A.; Wang, L.; Zimmermann, M.T.; Chambwe, N.; Gao, G.F.; Cherniack, A.D.; Fan, H.; Shen, H.; Way, G.P.; Greene, C.S.; et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018, 23, 239–254.e236. [CrossRef] [PubMed] 26. Peng, X.; Chen, Z.; Farshidfar, F.; Xu, X.; Lorenzi, P.L.; Wang, Y.; Cheng, F.; Tan, L.; Mojumdar, K.; Du, D.; et al. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep. 2018, 23, 255–269.e254. [CrossRef] 27. Seiler, M.; Peng, S.; Agrawal, A.A.; Palacino, J.; Teng, T.; Zhu, P.; Smith, P.G.; Cancer Genome Atlas Research, N.; Buonamici, S.; Yu, L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep. 2018, 23, 282–296.e284. [CrossRef] 28. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity 2018, 48, 812–830.e814. [CrossRef] 29. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [CrossRef] 30. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408, 307–310. [CrossRef] 31. Oren, M. Decision making by p53: Life, death and cancer. Cell Death Differ. 2003, 10, 431–442. [CrossRef] 32. Harris, S.L.; Levine, A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 2005, 24, 2899–2908. [CrossRef] [PubMed] 33. Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18, 283–293. [CrossRef] [PubMed] 34. Labuschagne, C.F.; Zani, F.; Vousden, K.H. Control of metabolism by p53–Cancer and beyond. Biochim. Biophys. Acta Rev. Cancer 2018, 1870, 32–42. [CrossRef] [PubMed] 35. Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 2009, 9, 749–758. [CrossRef] [PubMed] 36. Aubrey, B.J.; Strasser, A.; Kelly, G.L. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb. Perspect. Med. 2016, 6, a026062. [CrossRef] [PubMed] 37. Haronikova, L.; Olivares-Illana, V.; Wang, L.; Karakostis, K.; Chen, S.; Fahraeus, R. The p53 mRNA: An integral part of the cellular stress response. Nucleic Acids Res. 2019, 47, 3257–3271. [CrossRef] 38. Muller, P.A.; Vousden, K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15, 2–8. [CrossRef] 39. Li, J.; Yang, L.; Gaur, S.; Zhang, K.; Wu, X.; Yuan, Y.C.; Li, H.; Hu, S.; Weng, Y.; Yen, Y. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum. Mutat. 2014, 35, 575–584. [CrossRef] 40. Sun, S.; Chen, H.; Sun, L.; Wang, M.; Wu, X.; Xiao, Z.J. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis. Cell Death Dis. 2020, 11, 595. [CrossRef] 41. Schulz-Heddergott, R.; Stark, N.; Edmunds, S.J.; Li, J.; Conradi, L.C.; Bohnenberger, H.; Ceteci, F.; Greten, F.R.; Dobbelstein, M.; Moll, U.M. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell 2018, 34, 298–314.e297. [CrossRef] 42. Klemke, L.; Fehlau, C.F.; Winkler, N.; Toboll, F.; Singh, S.K.; Moll, U.M.; Schulz-Heddergott, R. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Front. Oncol. 2021, 11, 642603. [CrossRef] [PubMed] 43. Yu, X.; Vazquez, A.; Levine, A.J.; Carpizo, D.R. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21, 614–625. [CrossRef] [PubMed] 44. Grugan, K.D.; Vega, M.E.; Wong, G.S.; Diehl, J.A.; Bass, A.J.; Wong, K.K.; Nakagawa, H.; Rustgi, A.K. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol. Ther. 2013, 14, 853–859. [CrossRef] [PubMed] 45. Parry, D.; Peters, G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol. Cell Biol. 1996, 16, 3844–3852. [CrossRef] 46. Rutter, J.L.; Goldstein, A.M.; Davila, M.R.; Tucker, M.A.; Struewing, J.P. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 2003, 22, 4444–4448. [CrossRef] 47. Kannengiesser, C.; Brookes, S.; del Arroyo, A.G.; Pham, D.; Bombled, J.; Barrois, M.; Mauffret, O.; Avril, M.F.; Chompret, A.; Lenoir, G.M.; et al. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma- prone families or patients. Hum. Mutat. 2009, 30, 564–574. [CrossRef] Cancers 2022, 14, 664 24 of 32 48. Angele, S.; Jones, C.; Reis Filho, J.S.; Fulford, L.G.; Treilleux, I.; Lakhani, S.R.; Hall, J. Expression of ATM, p53, and the MRE11- Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J. Clin. Pathol. 2004, 57, 1179–1184. [CrossRef] 49. Bailey, S.L.; Gurley, K.E.; Hoon-Kim, K.; Kelly-Spratt, K.S.; Kemp, C.J. Tumor suppression by p53 in the absence of Atm. Mol. Cancer Res. 2008, 6, 1185–1192. [CrossRef] 50. Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013, 19, 3189–3200. [CrossRef] 51. Malbert-Colas, L.; Ponnuswamy, A.; Olivares-Illana, V.; Tournillon, A.S.; Naski, N.; Fahraeus, R. HDMX folds the nascent p53 mRNA following activation by the ATM kinase. Mol. Cell 2014, 54, 500–511. [CrossRef] 52. Chwastek, J.; Jantas, D.; Lason, W. The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide- induced cell damage via a gammaH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D. Int. J. Biochem. Cell Biol. 2017, 87, 38–53. [CrossRef] [PubMed] 53. Karakostis, K.; Vadivel Gnanasundram, S.; Lopez, I.; Thermou, A.; Wang, L.; Nylander, K.; Olivares-Illana, V.; Fahraeus, R. A single synonymous mutation determines the phosphorylation and stability of the nascent protein. J. Mol. Cell Biol. 2019, 11, 187–199. [CrossRef] [PubMed] 54. Hwang, S.Y.; Kuk, M.U.; Kim, J.W.; Lee, Y.H.; Lee, Y.S.; Choy, H.E.; Park, S.C.; Park, J.T. ATM mediated-p53 signaling pathway forms a novel axis for senescence control. Mitochondrion 2020, 55, 54–63. [CrossRef] [PubMed] 55. Easton, D.F.; Pharoah, P.D.; Antoniou, A.C.; Tischkowitz, M.; Tavtigian, S.V.; Nathanson, K.L.; Devilee, P.; Meindl, A.; Couch, F.J.; Southey, M.; et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 2015, 372, 2243–2257. [CrossRef] 56. Griffith, O.L.; Spies, N.C.; Anurag, M.; Griffith, M.; Luo, J.; Tu, D.; Yeo, B.; Kunisaki, J.; Miller, C.A.; Krysiak, K.; et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat. Commun. 2018, 9, 3476. [CrossRef] 57. Nahar, R.; Zhai, W.; Zhang, T.; Takano, A.; Khng, A.J.; Lee, Y.Y.; Liu, X.; Lim, C.H.; Koh, T.P.T.; Aung, Z.W.; et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat. Commun. 2018, 9, 216. [CrossRef] 58. Jette, N.R.; Kumar, M.; Radhamani, S.; Arthur, G.; Goutam, S.; Yip, S.; Kolinsky, M.; Williams, G.J.; Bose, P.; Lees-Miller, S.P. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers 2020, 12, 687. [CrossRef] 59. Zhu, G.; Pan, C.; Bei, J.X.; Li, B.; Liang, C.; Xu, Y.; Fu, X. Mutant p53 in Cancer Progression and Targeted Therapies. Front. Oncol. 2020, 10, 595187. [CrossRef] 60. Salomao, N.; Karakostis, K.; Hupp, T.; Vollrath, F.; Vojtesek, B.; Fahraeus, R. What do we need to know and understand about p53 to improve its clinical value? J. Pathol. 2021, 254, 443–453. [CrossRef] 61. Duffy, M.J.; Synnott, N.C.; O’Grady, S.; Crown, J. Targeting p53 for the treatment of cancer. Semin. Cancer Biol. 2020. [CrossRef] 62. Dhillon, S. Palbociclib: First global approval. Drugs 2015, 75, 543–551. [CrossRef] [PubMed] 63. Kim, E.S. Abemaciclib: First Global Approval. Drugs 2017, 77, 2063–2070. [CrossRef] [PubMed] 64. Syed, Y.Y. Ribociclib: First Global Approval. Drugs 2017, 77, 799–807. [CrossRef] 65. Dhillon, S. Trilaciclib: First Approval. Drugs 2021, 81, 867–874. [CrossRef] [PubMed] 66. Young, R.J.; Waldeck, K.; Martin, C.; Foo, J.H.; Cameron, D.P.; Kirby, L.; Do, H.; Mitchell, C.; Cullinane, C.; Liu, W.; et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014, 27, 590–600. [CrossRef] 67. Su, D.; Zhang, D.; Jin, J.; Ying, L.; Han, M.; Chen, K.; Li, B.; Wu, J.; Xie, Z.; Zhang, F.; et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat. Commun. 2019, 10, 5076. [CrossRef] 68. DeMichele, A.; Clark, A.S.; Tan, K.S.; Heitjan, D.F.; Gramlich, K.; Gallagher, M.; Lal, P.; Feldman, M.; Zhang, P.; Colameco, C.; et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 2015, 21, 995–1001. [CrossRef] 69. Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015, 16, 25–35. [CrossRef] 70. Arnedos, M.; Bayar, M.A.; Cheaib, B.; Scott, V.; Bouakka, I.; Valent, A.; Adam, J.; Leroux-Kozal, V.; Marty, V.; Rapinat, A.; et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: The preoperative-palbociclib (POP) randomized clinical trial. Ann. Oncol. 2018, 29, 1755–1762. [CrossRef] 71. Rose, T.L.; Chism, D.D.; Alva, A.S.; Deal, A.M.; Maygarden, S.J.; Whang, Y.E.; Kardos, J.; Drier, A.; Basch, E.; Godley, P.A.; et al. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. Br. J. Cancer 2018, 119, 801–807. [CrossRef] 72. Toulmonde, M.; Blay, J.Y.; Bouche, O.; Mir, O.; Penel, N.; Isambert, N.; Duffaud, F.; Bompas, E.; Esnaud, T.; Boidot, R.; et al. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clin. Cancer Res. 2019, 25, 4611–4615. [CrossRef] [PubMed] Cancers 2022, 14, 664 25 of 32 73. Mateo, J.; Carreira, S.; Sandhu, S.; Miranda, S.; Mossop, H.; Perez-Lopez, R.; Nava Rodrigues, D.; Robinson, D.; Omlin, A.; Tunariu, N.; et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. Engl. J. Med. 2015, 373, 1697–1708. [CrossRef] [PubMed] 74. Schmitt, A.; Knittel, G.; Welcker, D.; Yang, T.P.; George, J.; Nowak, M.; Leeser, U.; Buttner, R.; Perner, S.; Peifer, M.; et al. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Res. 2017, 77, 3040–3056. [CrossRef] [PubMed] 75. Lloyd, R.L.; Wijnhoven, P.W.G.; Ramos-Montoya, A.; Wilson, Z.; Illuzzi, G.; Falenta, K.; Jones, G.N.; James, N.; Chabbert, C.D.; Stott, J.; et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 2020, 39, 4869–4883. [CrossRef] [PubMed] 76. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3, 11–22. [CrossRef] 77. Castellano, E.; Molina-Arcas, M.; Krygowska, A.A.; East, P.; Warne, P.; Nicol, A.; Downward, J. RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. Nat. Commun. 2016, 7, 11245. [CrossRef] 78. Imperial, R.; Toor, O.M.; Hussain, A.; Subramanian, J.; Masood, A. Comprehensive pancancer genomic analysis reveals (RTK)- RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Semin. Cancer Biol. 2019, 54, 14–28. [CrossRef] 79. Smith, M.J.; Neel, B.G.; Ikura, M. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc. Natl. Acad. Sci. USA 2013, 110, 4574–4579. [CrossRef] 80. Cook, J.H.; Melloni, G.E.M.; Gulhan, D.C.; Park, P.J.; Haigis, K.M. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 2021, 12, 1808. [CrossRef] 81. Feig, L.A.; Cooper, G.M. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol. Cell Biol. 1988, 8, 2472–2478. [CrossRef] 82. Poulin, E.J.; Bera, A.K.; Lu, J.; Lin, Y.J.; Strasser, S.D.; Paulo, J.A.; Huang, T.Q.; Morales, C.; Yan, W.; Cook, J.; et al. Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov. 2019, 9, 738–755. [CrossRef] [PubMed] 83. Waters, A.M.; Der, C.J. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb. Perspect. Med. 2018, 8, a031435. [CrossRef] [PubMed] 84. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [CrossRef] [PubMed] 85. Cantwell-Dorris, E.R.; O’Leary, J.J.; Sheils, O.M. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 2011, 10, 385–394. [CrossRef] 86. Falini, B.; Martelli, M.P.; Tiacci, E. BRAF V600E mutation in hairy cell leukemia: From bench to bedside. Blood 2016, 128, 1918–1927. [CrossRef] 87. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069–1075. [CrossRef] 88. Upadhyaya, M.; Kluwe, L.; Spurlock, G.; Monem, B.; Majounie, E.; Mantripragada, K.; Ruggieri, M.; Chuzhanova, N.; Evans, D.G.; Ferner, R.; et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum. Mutat. 2008, 29, 74–82. [CrossRef] 89. Brems, H.; Beert, E.; de Ravel, T.; Legius, E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009, 10, 508–515. [CrossRef] 90. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [CrossRef] 91. Dumbrava, E.I.; Meric-Bernstam, F. Personalized cancer therapy-leveraging a knowledge base for clinical decision-making. Cold Spring Harb. Mol. Case Stud. 2018, 4, a001578. [CrossRef] 92. Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 2014, 13, 828–851. [CrossRef] [PubMed] 93. Keeton, A.B.; Salter, E.A.; Piazza, G.A. The RAS-Effector Interaction as a Drug Target. Cancer Res. 2017, 77, 221–226. [CrossRef] [PubMed] 94. Liu, P.; Wang, Y.; Li, X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm. Sin. B 2019, 9, 871–879. [CrossRef] [PubMed] 95. Sheridan, C. Grail of RAS cancer drugs within reach. Nat. Biotechnol. 2020, 38, 6–8. [CrossRef] [PubMed] 96. Blair, H.A. Sotorasib: First Approval. Drugs 2021, 81, 1573–1579. [CrossRef] 97. Riely, G.J.; Ou, S.H.I.; Rybkin, I.; Spira, A.; Papadopoulos, K.; Sabari, J.K.; Johnson, M.; Heist, R.S.; Bazhenova, L.; Barve, M.; et al. 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation. J. Thorac. Oncol. 2021, 16, S751–S752. [CrossRef] 98. Flaherty, K.T.; Yasothan, U.; Kirkpatrick, P. Vemurafenib. Nat. Rev. Drug Discov. 2011, 10, 811–812. [CrossRef] 99. Ballantyne, A.D.; Garnock-Jones, K.P. Dabrafenib: First global approval. Drugs 2013, 73, 1367–1376. [CrossRef] 100. Dummer, R.; Ascierto, P.A.; Gogas, H.J.; Arance, A.; Mandala, M.; Liszkay, G.; Garbe, C.; Schadendorf, D.; Krajsova, I.; Gutzmer, R.; et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018, 19, 603–615. [CrossRef] 101. Zhou, D.; Mattner, J.; Cantu, C., 3rd; Schrantz, N.; Yin, N.; Gao, Y.; Sagiv, Y.; Hudspeth, K.; Wu, Y.P.; Yamashita, T.; et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306, 1786–1789. [CrossRef] Cancers 2022, 14, 664 26 of 32 102. Groux-Degroote, S.; van Dijk, S.M.; Wolthoorn, J.; Neumann, S.; Theos, A.C.; De Maziere, A.M.; Klumperman, J.; van Meer, G.; Sprong, H. Glycolipid-dependent sorting of melanosomal from lysosomal membrane proteins by lumenal determinants. Traffic 2008, 9, 951–963. [CrossRef] [PubMed] 103. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181–193. [CrossRef] [PubMed] 104. Hishikawa, D.; Hashidate, T.; Shimizu, T.; Shindou, H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J. Lipid Res. 2014, 55, 799–807. [CrossRef] [PubMed] 105. Gyamfi, D.; Ofori Awuah, E.; Owusu, S. Chapter 2—Lipid Metabolism: An Overview. In The Molecular Nutrition of Fats; Patel, V.B., Ed.; Academic Press: Cambridge, MA, USA, 2019; pp. 17–32. [CrossRef] 106. DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7, 11–20. [CrossRef] [PubMed] 107. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033. [CrossRef] 108. Zhao, L.; Vogt, P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 2008, 105, 2652–2657. [CrossRef] 109. Leontiadou, H.; Galdadas, I.; Athanasiou, C.; Cournia, Z. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Sci. Rep. 2018, 8, 15544. [CrossRef] 110. Gkeka, P.; Evangelidis, T.; Pavlaki, M.; Lazani, V.; Christoforidis, S.; Agianian, B.; Cournia, Z. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. PLoS Comput. Biol. 2014, 10, e1003895. [CrossRef] 111. Ikenoue, T.; Kanai, F.; Hikiba, Y.; Obata, T.; Tanaka, Y.; Imamura, J.; Ohta, M.; Jazag, A.; Guleng, B.; Tateishi, K.; et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005, 65, 4562–4567. [CrossRef] 112. Kang, S.; Bader, A.G.; Vogt, P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA 2005, 102, 802–807. [CrossRef] 113. Bader, A.G.; Kang, S.; Vogt, P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 1475–1479. [CrossRef] [PubMed] 114. Dogruluk, T.; Tsang, Y.H.; Espitia, M.; Chen, F.; Chen, T.; Chong, Z.; Appadurai, V.; Dogruluk, A.; Eterovic, A.K.; Bonnen, P.E.; et al. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res. 2015, 75, 5341–5354. [CrossRef] [PubMed] 115. Rohrig, F.; Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 2016, 16, 732–749. [CrossRef] [PubMed] 116. Snaebjornsson, M.T.; Janaki-Raman, S.; Schulze, A. Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metab. 2020, 31, 62–76. [CrossRef] 117. Georgescu, M.M.; Kirsch, K.H.; Akagi, T.; Shishido, T.; Hanafusa, H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. USA 1999, 96, 10182–10187. [CrossRef] [PubMed] 118. Papa, A.; Wan, L.; Bonora, M.; Salmena, L.; Song, M.S.; Hobbs, R.M.; Lunardi, A.; Webster, K.; Ng, C.; Newton, R.H.; et al. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell 2014, 157, 595–610. [CrossRef] 119. Rashmi, R.; DeSelm, C.; Helms, C.; Bowcock, A.; Rogers, B.E.; Rader, J.L.; Rader, J.; Grigsby, P.W.; Schwarz, J.K. AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS ONE 2014, 9, e92948. [CrossRef] 120. Leslie, N.R.; den Hertog, J. Mutant PTEN in Cancer: Worse Than Nothing. Cell 2014, 157, 527–529. [CrossRef] 121. Salmena, L.; Carracedo, A.; Pandolfi, P.P. Tenets of PTEN tumor suppression. Cell 2008, 133, 403–414. [CrossRef] 122. Choi, S.W.; Lee, Y.; Shin, K.; Koo, H.; Kim, D.; Sa, J.K.; Cho, H.J.; Shin, H.M.; Lee, S.J.; Kim, H.; et al. Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death Dis. 2021, 12, 374. [CrossRef] 123. Kloosterhof, N.K.; Bralten, L.B.; Dubbink, H.J.; French, P.J.; van den Bent, M.J. Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011, 12, 83–91. [CrossRef] 124. Clark, O.; Yen, K.; Mellinghoff, I.K. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin. Cancer Res. 2016, 22, 1837–1842. [CrossRef] [PubMed] 125. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittinger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465, 966. [CrossRef] 126. Shim, E.H.; Livi, C.B.; Rakheja, D.; Tan, J.; Benson, D.; Parekh, V.; Kho, E.Y.; Ghosh, A.P.; Kirkman, R.; Velu, S.; et al. L-2-Hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014, 4, 1290–1298. [CrossRef] [PubMed] 127. Parker, S.J.; Metallo, C.M. Metabolic consequences of oncogenic IDH mutations. Pharmacol. Ther. 2015, 152, 54–62. [CrossRef] [PubMed] 128. Yang, H.; Ye, D.; Guan, K.L.; Xiong, Y. IDH1 and IDH2 mutations in tumorigenesis: Mechanistic insights and clinical perspectives. Clin. Cancer Res. 2012, 18, 5562–5571. [CrossRef] 129. Reitman, Z.J.; Jin, G.; Karoly, E.D.; Spasojevic, I.; Yang, J.; Kinzler, K.W.; He, Y.; Bigner, D.D.; Vogelstein, B.; Yan, H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 2011, 108, 3270–3275. [CrossRef] [PubMed] Cancers 2022, 14, 664 27 of 32 130. Esmaeili, M.; Hamans, B.C.; Navis, A.C.; van Horssen, R.; Bathen, T.F.; Gribbestad, I.S.; Leenders, W.P.; Heerschap, A. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res. 2014, 74, 4898–4907. [CrossRef] 131. Zhou, L.; Wang, Z.; Hu, C.; Zhang, C.; Kovatcheva-Datchary, P.; Yu, D.; Liu, S.; Ren, F.; Wang, X.; Li, Y.; et al. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. J. Proteome Res. 2019, 18, 960–969. [CrossRef] 132. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 2271–2281. [CrossRef] 133. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449–456. [CrossRef] 134. Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M.N. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10, 868–880. [CrossRef] [PubMed] 135. Blair, H.A. Duvelisib: First Global Approval. Drugs 2018, 78, 1847–1853. [CrossRef] [PubMed] 136. Markham, A. Alpelisib: First Global Approval. Drugs 2019, 79, 1249–1253. [CrossRef] [PubMed] 137. Dhillon, S. Ivosidenib: First Global Approval. Drugs 2018, 78, 1509–1516. [CrossRef] 138. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M.D. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17, 615–675. [CrossRef] 139. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7, 606–619. [CrossRef] 140. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075–1083. [CrossRef] 141. Fruman, D.A.; Chiu, H.; Hopkins, B.D.; Bagrodia, S.; Cantley, L.C.; Abraham, R.T. The PI3K Pathway in Human Disease. Cell 2017, 170, 605–635. [CrossRef] 142. Cheung, L.W.; Yu, S.; Zhang, D.; Li, J.; Ng, P.K.; Panupinthu, N.; Mitra, S.; Ju, Z.; Yu, Q.; Liang, H.; et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 2014, 26, 479–494. [CrossRef] 143. Seton-Rogers, S. Signalling: Uncovering new functions of PI3K mutations. Nat. Rev. Cancer 2014, 14, 766–767. [CrossRef] [PubMed] 144. Moukarzel, L.A.; Da Cruz Paula, A.; Ferrando, L.; Hoang, T.; Sebastiao, A.P.M.; Pareja, F.; Park, K.J.; Jungbluth, A.A.; Capella, G.; Pineda, M.; et al. Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Mod. Pathol. 2021, 34, 994–1007. [CrossRef] [PubMed] 145. Sun, M.; Hillmann, P.; Hofmann, B.T.; Hart, J.R.; Vogt, P.K. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc. Natl. Acad. Sci. USA 2010, 107, 15547–15552. [CrossRef] [PubMed] 146. Li, X.; Lau, A.Y.T.; Ng, A.S.N.; Aldehaiman, A.; Zhou, Y.; Ng, P.K.S.; Arold, S.T.; Cheung, L.W.T. Cancer-associated mutations in the p85alpha N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases. Proc. Natl. Acad. Sci. USA 2021, 118, e2101751118. [CrossRef] [PubMed] 147. Song, M.; Bode, A.M.; Dong, Z.; Lee, M.H. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019, 79, 1019–1031. [CrossRef] [PubMed] 148. Martorana, F.; Motta, G.; Pavone, G.; Motta, L.; Stella, S.; Vitale, S.R.; Manzella, L.; Vigneri, P. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? Front. Pharmacol. 2021, 12, 662232. [CrossRef] 149. Adamaki, M.; Zoumpourlis, V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol. Ther. 2021, 228, 107932. [CrossRef] 150. Deng, L.; Wang, C.; Spencer, E.; Yang, L.; Braun, A.; You, J.; Slaughter, C.; Pickart, C.; Chen, Z.J. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103, 351–361. [CrossRef] 151. Pickart, C.M. Ubiquitin in chains. Trends Biochem. Sci. 2000, 25, 544–548. [CrossRef] 152. Spence, J.; Gali, R.R.; Dittmar, G.; Sherman, F.; Karin, M.; Finley, D. Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000, 102, 67–76. [CrossRef] 153. Huen, M.S.; Grant, R.; Manke, I.; Minn, K.; Yu, X.; Yaffe, M.B.; Chen, J. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007, 131, 901–914. [CrossRef] [PubMed] 154. Mukhopadhyay, D.; Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007, 315, 201–205. [CrossRef] [PubMed] 155. Yumimoto, K.; Akiyoshi, S.; Ueo, H.; Sagara, Y.; Onoyama, I.; Ueo, H.; Ohno, S.; Mori, M.; Mimori, K.; Nakayama, K.I. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J. Clin. Investig. 2015, 125, 621–635. [CrossRef] [PubMed] 156. Yeh, C.H.; Bellon, M.; Nicot, C. FBXW7: A critical tumor suppressor of human cancers. Mol. Cancer 2018, 17, 115. [CrossRef] Cancers 2022, 14, 664 28 of 32 157. Close, V.; Close, W.; Kugler, S.J.; Reichenzeller, M.; Yosifov, D.Y.; Bloehdorn, J.; Pan, L.; Tausch, E.; Westhoff, M.A.; Dohner, H.; et al. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood 2019, 133, 830–839. [CrossRef] [PubMed] 158. Koepp, D.M.; Schaefer, L.K.; Ye, X.; Keyomarsi, K.; Chu, C.; Harper, J.W.; Elledge, S.J. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001, 294, 173–177. [CrossRef] 159. Oberg, C.; Li, J.; Pauley, A.; Wolf, E.; Gurney, M.; Lendahl, U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J. Biol. Chem. 2001, 276, 35847–35853. [CrossRef] 160. Yada, M.; Hatakeyama, S.; Kamura, T.; Nishiyama, M.; Tsunematsu, R.; Imaki, H.; Ishida, N.; Okumura, F.; Nakayama, K.; Nakayama, K.I. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004, 23, 2116–2125. [CrossRef] 161. Wei, W.; Jin, J.; Schlisio, S.; Harper, J.W.; Kaelin, W.G., Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005, 8, 25–33. [CrossRef] 162. Mao, J.H.; Kim, I.J.; Wu, D.; Climent, J.; Kang, H.C.; DelRosario, R.; Balmain, A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321, 1499–1502. [CrossRef] 163. Inuzuka, H.; Shaik, S.; Onoyama, I.; Gao, D.; Tseng, A.; Maser, R.S.; Zhai, B.; Wan, L.; Gutierrez, A.; Lau, A.W.; et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471, 104–109. [CrossRef] [PubMed] 164. Liu, X.; Wang, L.; Zhao, K.; Thompson, P.R.; Hwang, Y.; Marmorstein, R.; Cole, P.A. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008, 451, 846–850. [CrossRef] [PubMed] 165. Delvecchio, M.; Gaucher, J.; Aguilar-Gurrieri, C.; Ortega, E.; Panne, D. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation. Nat. Struct. Mol. Biol. 2013, 20, 1040–1046. [CrossRef] [PubMed] 166. Pao, G.M.; Janknecht, R.; Ruffner, H.; Hunter, T.; Verma, I.M. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc. Natl. Acad. Sci. USA 2000, 97, 1020–1025. [CrossRef] 167. Chan, H.M.; Krstic-Demonacos, M.; Smith, L.; Demonacos, C.; La Thangue, N.B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 2001, 3, 667–674. [CrossRef] 168. Grossman, S.R. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 2001, 268, 2773–2778. [CrossRef] 169. Friedrichs, N.; Jager, R.; Paggen, E.; Rudlowski, C.; Merkelbach-Bruse, S.; Schorle, H.; Buettner, R. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod. Pathol. 2005, 18, 431–438. [CrossRef] 170. Salloum, R.; McConechy, M.K.; Mikael, L.G.; Fuller, C.; Drissi, R.; DeWire, M.; Nikbakht, H.; De Jay, N.; Yang, X.; Boue, D.; et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathol. Commun. 2017, 5, 78. [CrossRef] 171. Shi, D.; Pop, M.S.; Kulikov, R.; Love, I.M.; Kung, A.L.; Grossman, S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. USA 2009, 106, 16275–16280. [CrossRef] 172. Fahraeus, R.; Olivares-Illana, V. MDM2’s social network. Oncogene 2014, 33, 4365–4376. [CrossRef] 173. Klein, A.M.; de Queiroz, R.M.; Venkatesh, D.; Prives, C. The roles and regulation of MDM2 and MDMX: It is not just about p53. Genes Dev. 2021, 35, 575–601. [CrossRef] [PubMed] 174. Attar, N.; Kurdistani, S.K. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harb. Perspect. Med. 2017, 7, a026534. [CrossRef] [PubMed] 175. Pasqualucci, L.; Dominguez-Sola, D.; Chiarenza, A.; Fabbri, G.; Grunn, A.; Trifonov, V.; Kasper, L.H.; Lerach, S.; Tang, H.; Ma, J.; et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471, 189–195. [CrossRef] 176. Peifer, M.; Fernandez-Cuesta, L.; Sos, M.L.; George, J.; Seidel, D.; Kasper, L.H.; Plenker, D.; Leenders, F.; Sun, R.; Zander, T.; et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44, 1104–1110. [CrossRef] [PubMed] 177. Merk, D.J.; Ohli, J.; Merk, N.D.; Thatikonda, V.; Morrissy, S.; Schoof, M.; Schmid, S.N.; Harrison, L.; Filser, S.; Ahlfeld, J.; et al. Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. Dev. Cell 2018, 44, 709–724.e706. [CrossRef] [PubMed] 178. Mondello, P.; Tadros, S.; Teater, M.; Fontan, L.; Chang, A.Y.; Jain, N.; Yang, H.; Singh, S.; Ying, H.Y.; Chu, C.S.; et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020, 10, 440–459. [CrossRef] 179. Deng, L.; Meng, T.; Chen, L.; Wei, W.; Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target. Ther. 2020, 5, 11. [CrossRef] 180. Lu, G.; Middleton, R.E.; Sun, H.; Naniong, M.; Ott, C.J.; Mitsiades, C.S.; Wong, K.K.; Bradner, J.E.; Kaelin, W.G., Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343, 305–309. [CrossRef] 181. Stewart, A.K. Medicine. How thalidomide works against cancer. Science 2014, 343, 256–257. [CrossRef] 182. Fricker, L.D. Proteasome Inhibitor Drugs. Annu. Rev. Pharmacol. Toxicol. 2020, 60, 457–476. [CrossRef] 183. Dick, L.R.; Fleming, P.E. Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 2010, 15, 243–249. [CrossRef] [PubMed] 184. Nelson, W.J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303, 1483–1487. [CrossRef] [PubMed] Cancers 2022, 14, 664 29 of 32 185. Gattinoni, L.; Zhong, X.S.; Palmer, D.C.; Ji, Y.; Hinrichs, C.S.; Yu, Z.; Wrzesinski, C.; Boni, A.; Cassard, L.; Garvin, L.M.; et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 2009, 15, 808–813. [CrossRef] 186. Petersen, C.P.; Reddien, P.W. Wnt signaling and the polarity of the primary body axis. Cell 2009, 139, 1056–1068. [CrossRef] 187. Spranger, S.; Gajewski, T.F. A new paradigm for tumor immune escape: Beta-catenin-driven immune exclusion. J. Immunother. Cancer 2015, 3, 43. [CrossRef] [PubMed] 188. Junge, H.J. Ligand-Selective Wnt Receptor Complexes in CNS Blood Vessels: RECK and GPR124 Plugged In. Neuron 2017, 95, 983–985. [CrossRef] 189. Miyoshi, Y.; Nagase, H.; Ando, H.; Horii, A.; Ichii, S.; Nakatsuru, S.; Aoki, T.; Miki, Y.; Mori, T.; Nakamura, Y. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum. Mol. Genet. 1992, 1, 229–233. [CrossRef] 190. Fearnhead, N.S.; Britton, M.P.; Bodmer, W.F. The ABC of APC. Hum. Mol. Genet. 2001, 10, 721–733. [CrossRef] 191. Azzopardi, D.; Dallosso, A.R.; Eliason, K.; Hendrickson, B.C.; Jones, N.; Rawstorne, E.; Colley, J.; Moskvina, V.; Frye, C.; Sampson, J.R.; et al. Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res. 2008, 68, 358–363. [CrossRef] 192. Pai, S.G.; Carneiro, B.A.; Mota, J.M.; Costa, R.; Leite, C.A.; Barroso-Sousa, R.; Kaplan, J.B.; Chae, Y.K.; Giles, F.J. Wnt/beta-catenin pathway: Modulating anticancer immune response. J. Hematol. Oncol. 2017, 10, 101. [CrossRef] 193. Imperial, R.; Ahmed, Z.; Toor, O.M.; Erdogan, C.; Khaliq, A.; Case, P.; Case, J.; Kennedy, K.; Cummings, L.S.; Melton, N.; et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Mol. Cancer 2018, 17, 177. [CrossRef] [PubMed] 194. Ficari, F.; Cama, A.; Valanzano, R.; Curia, M.C.; Palmirotta, R.; Aceto, G.; Esposito, D.L.; Crognale, S.; Lombardi, A.; Messerini, L.; et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br. J. Cancer 2000, 82, 348–353. [CrossRef] [PubMed] 195. Mihalatos, M.; Danielides, I.; Belogianni, J.; Harokopos, E.; Papadopoulou, E.; Kalimanis, G.; Tsiava, M.; Triantafillidis, J.K.; Kosmidis, P.A.; Fountzilas, G.; et al. Novel mutations of the APC gene in familial adenomatous polyposis in Greek patients. Cancer Genet. Cytogenet. 2003, 141, 65–70. [CrossRef] 196. Kitagawa, M.; Hatakeyama, S.; Shirane, M.; Matsumoto, M.; Ishida, N.; Hattori, K.; Nakamichi, I.; Kikuchi, A.; Nakayama, K.; Nakayama, K. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 1999, 18, 2401–2410. [CrossRef] [PubMed] 197. Kikuchi, A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003, 94, 225–229. [CrossRef] 198. Morin, P.J.; Sparks, A.B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275, 1787–1790. [CrossRef] 199. Rubinfeld, B.; Robbins, P.; El-Gamil, M.; Albert, I.; Porfiri, E.; Polakis, P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997, 275, 1790–1792. [CrossRef] 200. Liu, C.; Li, Y.; Semenov, M.; Han, C.; Baeg, G.H.; Tan, Y.; Zhang, Z.; Lin, X.; He, X. Control of beta-catenin phosphoryla- tion/degradation by a dual-kinase mechanism. Cell 2002, 108, 837–847. [CrossRef] 201. Rebouissou, S.; Franconi, A.; Calderaro, J.; Letouze, E.; Imbeaud, S.; Pilati, C.; Nault, J.C.; Couchy, G.; Laurent, A.; Balabaud, C.; et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology 2016, 64, 2047–2061. [CrossRef] 202. Tu, J.; Park, S.; Yu, W.; Zhang, S.; Wu, L.; Carmon, K.; Liu, Q.J. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 2019, 9, 18557. [CrossRef] 203. Hao, H.X.; Xie, Y.; Zhang, Y.; Charlat, O.; Oster, E.; Avello, M.; Lei, H.; Mickanin, C.; Liu, D.; Ruffner, H.; et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012, 485, 195–200. [CrossRef] [PubMed] 204. Koo, B.K.; Spit, M.; Jordens, I.; Low, T.Y.; Stange, D.E.; van de Wetering, M.; van Es, J.H.; Mohammed, S.; Heck, A.J.; Maurice, M.M.; et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 2012, 488, 665–669. [CrossRef] [PubMed] 205. UniProt, C. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 2021, 49, D480–D489. [CrossRef] 206. Spit, M.; Fenderico, N.; Jordens, I.; Radaszkiewicz, T.; Lindeboom, R.G.; Bugter, J.M.; Cristobal, A.; Ootes, L.; van Osch, M.; Janssen, E.; et al. RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer. EMBO J. 2020, 39, e103932. [CrossRef] 207. Anastas, J.N.; Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13, 11–26. [CrossRef] 208. Jung, Y.S.; Park, J.I. Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. Exp. Mol. Med. 2020, 52, 183–191. [CrossRef] 209. Hori, K.; Sen, A.; Artavanis-Tsakonas, S. Notch signaling at a glance. J. Cell Sci. 2013, 126, 2135–2140. [CrossRef] 210. Bray, S.J. Notch signalling in context. Nat. Rev. Mol. Cell Biol. 2016, 17, 722–735. [CrossRef] 211. Siebel, C.; Lendahl, U. Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol. Rev. 2017, 97, 1235–1294. [CrossRef] 212. Pancewicz, J.; Taylor, J.M.; Datta, A.; Baydoun, H.H.; Waldmann, T.A.; Hermine, O.; Nicot, C. Notch signaling contributes to pro- liferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc. Natl. Acad. Sci. USA 2010, 107, 16619–16624. [CrossRef] Cancers 2022, 14, 664 30 of 32 213. Yeh, C.H.; Bellon, M.; Pancewicz-Wojtkiewicz, J.; Nicot, C. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc. Natl. Acad. Sci. USA 2016, 113, 6731–6736. [CrossRef] [PubMed] 214. Oswald, F.; Tauber, B.; Dobner, T.; Bourteele, S.; Kostezka, U.; Adler, G.; Liptay, S.; Schmid, R.M. p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol. Cell Biol. 2001, 21, 7761–7774. [CrossRef] [PubMed] 215. Wallberg, A.E.; Pedersen, K.; Lendahl, U.; Roeder, R.G. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol. Cell Biol. 2002, 22, 7812–7819. [CrossRef] [PubMed] 216. Huang, Y.H.; Cai, K.; Xu, P.P.; Wang, L.; Huang, C.X.; Fang, Y.; Cheng, S.; Sun, X.J.; Liu, F.; Huang, J.Y.; et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct. Target. Ther. 2021, 6, 10. [CrossRef] 217. Majumder, S.; Crabtree, J.S.; Golde, T.E.; Minter, L.M.; Osborne, B.A.; Miele, L. Targeting Notch in oncology: The path forward. Nat. Rev. Drug Discov. 2021, 20, 125–144. [CrossRef] 218. Pannuti, A.; Foreman, K.; Rizzo, P.; Osipo, C.; Golde, T.; Osborne, B.; Miele, L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16, 3141–3152. [CrossRef] 219. Takebe, N.; Nguyen, D.; Yang, S.X. Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol. Ther. 2014, 141, 140–149. [CrossRef] 220. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9, 153–166. [CrossRef] 221. Matthews, H.K.; Bertoli, C.; de Bruin, R.A.M. Cell cycle control in cancer. Nat. Rev. Mol. Cell Biol. 2022, 23, 74–88. [CrossRef] 222. Cowell, J.K.; Smith, T.; Bia, B. Frequent constitutional C to T mutations in CGA-arginine codons in the RB1 gene produce premature stop codons in patients with bilateral (hereditary) retinoblastoma. Eur. J. Hum. Genet. 1994, 2, 281–290. [CrossRef] 223. Richter, S.; Vandezande, K.; Chen, N.; Zhang, K.; Sutherland, J.; Anderson, J.; Han, L.; Panton, R.; Branco, P.; Gallie, B. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am. J. Hum. Genet. 2003, 72, 253–269. [CrossRef] [PubMed] 224. Ayari Jeridi, H.; Bouguila, H.; Ansperger-Rescher, B.; Baroudi, O.; Mdimegh, I.; Omran, I.; Charradi, K.; Bouzayene, H.; Benammar- Elgaaied, A.; Lohmann, D.R. Genetic testing in Tunisian families with heritable retinoblastoma using a low cost approach permits accurate risk prediction in relatives and reveals incomplete penetrance in adults. Exp. Eye Res. 2014, 124, 48–55. [CrossRef] [PubMed] 225. Yu, H.A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M.G.; Hellmann, M.D.; Li, B.T.; Somwar, R.; et al. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clin. Cancer Res. 2018, 24, 3108–3118. [CrossRef] [PubMed] 226. Trimarchi, J.M.; Lees, J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3, 11–20. [CrossRef] 227. Burkhart, D.L.; Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 2008, 8, 671–682. [CrossRef] [PubMed] 228. Xiong, Y.; Hannon, G.J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366, 701–704. [CrossRef] 229. Waga, S.; Hannon, G.J.; Beach, D.; Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369, 574–578. [CrossRef] 230. Jackson, R.J.; Adnane, J.; Coppola, D.; Cantor, A.; Sebti, S.M.; Pledger, W.J. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002, 21, 8486–8497. [CrossRef] 231. Poole, A.J.; Heap, D.; Carroll, R.E.; Tyner, A.L. Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 2004, 23, 8128–8134. [CrossRef] 232. Forster, K.; Obermeier, A.; Mitina, O.; Simon, N.; Warmuth, M.; Krause, G.; Hallek, M. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Ann. Hematol. 2008, 87, 183–193. [CrossRef] 233. Suzuki, A.; Tsutomi, Y.; Miura, M.; Akahane, K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: Identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 1999, 18, 1239–1244. [CrossRef] [PubMed] 234. Yu, F.; Megyesi, J.; Safirstein, R.L.; Price, P.M. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am. J. Physiol. Renal Physiol. 2005, 289, F514–F520. [CrossRef] [PubMed] 235. Suski, J.M.; Braun, M.; Strmiska, V.; Sicinski, P. Targeting cell-cycle machinery in cancer. Cancer Cell 2021, 39, 759–778. [CrossRef] [PubMed] 236. Otto, T.; Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 2017, 17, 93–115. [CrossRef] [PubMed] 237. Karran, P. DNA double strand break repair in mammalian cells. Curr. Opin. Genet. Dev. 2000, 10, 144–150. [CrossRef] 238. Chen, C.C.; Feng, W.; Lim, P.X.; Kass, E.M.; Jasin, M. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. Annu. Rev. Cancer Biol. 2018, 2, 313–336. [CrossRef] 239. van Gent, D.C.; Hoeijmakers, J.H.; Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2001, 2, 196–206. [CrossRef] 240. Khanna, K.K.; Jackson, S.P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat. Genet. 2001, 27, 247–254. [CrossRef] Cancers 2022, 14, 664 31 of 32 241. Caburet, S.; Heddar, A.; Dardillac, E.; Creux, H.; Lambert, M.; Messiaen, S.; Tourpin, S.; Livera, G.; Lopez, B.S.; Misrahi, M. Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait. J. Med. Genet. 2020, 58, 125–134. [CrossRef] 242. Sun, P.; Li, Y.; Chao, X.; Li, J.; Luo, R.; Li, M.; He, J. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: A pan-tumor survey. BMC Cancer 2020, 20, 994. [CrossRef] 243. Lee, H. Cycling with BRCA2 from DNA repair to mitosis. Exp. Cell Res. 2014, 329, 78–84. [CrossRef] [PubMed] 244. Moynahan, M.E.; Pierce, A.J.; Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 2001, 7, 263–272. [CrossRef] 245. Tutt, A.; Bertwistle, D.; Valentine, J.; Gabriel, A.; Swift, S.; Ross, G.; Griffin, C.; Thacker, J.; Ashworth, A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 2001, 20, 4704–4716. [CrossRef] [PubMed] 246. Liu, J.; Doty, T.; Gibson, B.; Heyer, W.D. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single- stranded DNA. Nat. Struct. Mol. Biol. 2010, 17, 1260–1262. [CrossRef] [PubMed] 247. Rebbeck, T.R.; Friebel, T.M.; Friedman, E.; Hamann, U.; Huo, D.; Kwong, A.; Olah, E.; Olopade, O.I.; Solano, A.R.; Teo, S.H.; et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 2018, 39, 593–620. [CrossRef] [PubMed] 248. Scully, R.; Chen, J.; Plug, A.; Xiao, Y.; Weaver, D.; Feunteun, J.; Ashley, T.; Livingston, D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88, 265–275. [CrossRef] 249. Zhong, Q.; Chen, C.F.; Li, S.; Chen, Y.; Wang, C.C.; Xiao, J.; Chen, P.L.; Sharp, Z.D.; Lee, W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999, 285, 747–750. [CrossRef] 250. Clark, S.L.; Rodriguez, A.M.; Snyder, R.R.; Hankins, G.D.; Boehning, D. Structure-Function Of The Tumor Suppressor BRCA1. Comput. Struct. Biotechnol. J. 2012, 1, e201204005. [CrossRef] 251. Christou, C.M.; Kyriacou, K. BRCA1 and Its Network of Interacting Partners. Biology 2013, 2, 40–63. [CrossRef] 252. Bunting, S.F.; Callen, E.; Wong, N.; Chen, H.T.; Polato, F.; Gunn, A.; Bothmer, A.; Feldhahn, N.; Fernandez-Capetillo, O.; Cao, L.; et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141, 243–254. [CrossRef] 253. Zhang, J.; Yan, Z.; Wang, Y.; Wang, Y.; Guo, X.; Jing, J.; Dong, X.; Dong, S.; Liu, X.; Yu, X.; et al. Cancer-associated 53BP1 mutations induce DNA damage repair defects. Cancer Lett. 2021, 501, 43–54. [CrossRef] [PubMed] 254. Panier, S.; Boulton, S.J. Double-strand break repair: 53BP1 comes into focus. Nat. Rev. Mol. Cell Biol. 2014, 15, 7–18. [CrossRef] [PubMed] 255. Mao, Z.; Bozzella, M.; Seluanov, A.; Gorbunova, V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 2008, 7, 2902–2906. [CrossRef] [PubMed] 256. Yap, T.A.; Sandhu, S.K.; Carden, C.P.; de Bono, J.S. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 2011, 61, 31–49. [CrossRef] [PubMed] 257. Furgason, J.M.; Bahassi, E.M. Targeting DNA repair mechanisms in cancer. Pharmacol. Ther. 2013, 137, 298–308. [CrossRef] [PubMed] 258. Brown, J.S.; O’Carrigan, B.; Jackson, S.P.; Yap, T.A. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2017, 7, 20–37. [CrossRef] [PubMed] 259. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204. [CrossRef] 260. Deeks, E.D. Olaparib: First global approval. Drugs 2015, 75, 231–240. [CrossRef] 261. Scott, L.J. Niraparib: First Global Approval. Drugs 2017, 77, 1029–1034. [CrossRef] 262. Syed, Y.Y. Rucaparib: First Global Approval. Drugs 2017, 77, 585–592. [CrossRef] 263. Hoy, S.M. Talazoparib: First Global Approval. Drugs 2018, 78, 1939–1946. [CrossRef] [PubMed] 264. Arora, S.; Balasubramaniam, S.; Zhang, H.; Berman, T.; Narayan, P.; Suzman, D.; Bloomquist, E.; Tang, S.; Gong, Y.; Sridhara, R.; et al. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. Oncologist 2021, 26, e164–e172. [CrossRef] [PubMed] 265. Kwok, M.; Davies, N.; Agathanggelou, A.; Smith, E.; Oldreive, C.; Petermann, E.; Stewart, G.; Brown, J.; Lau, A.; Pratt, G.; et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 2016, 127, 582–595. [CrossRef] 266. Menolfi, D.; Zha, S. ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: Inhibition not equal deletion. Cell Biosci. 2020, 10, 8. [CrossRef] 267. Topatana, W.; Juengpanich, S.; Li, S.; Cao, J.; Hu, J.; Lee, J.; Suliyanto, K.; Ma, D.; Zhang, B.; Chen, M.; et al. Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation. J. Hematol. Oncol. 2020, 13, 118. [CrossRef] 268. David, C.J.; Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 2010, 24, 2343–2364. [CrossRef] [PubMed] 269. Dvinge, H.; Kim, E.; Abdel-Wahab, O.; Bradley, R.K. RNA splicing factors as oncoproteins and tumour suppressors. Nat. Rev. Cancer 2016, 16, 413–430. [CrossRef] Cancers 2022, 14, 664 32 of 32 270. Climente-Gonzalez, H.; Porta-Pardo, E.; Godzik, A.; Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Rep. 2017, 20, 2215–2226. [CrossRef] 271. Rahman, M.A.; Krainer, A.R.; Abdel-Wahab, O. SnapShot: Splicing Alterations in Cancer. Cell 2020, 180, 208.e201. [CrossRef] 272. Legare, S.; Cavallone, L.; Mamo, A.; Chabot, C.; Sirois, I.; Magliocco, A.; Klimowicz, A.; Tonin, P.N.; Buchanan, M.; Keilty, D.; et al. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. Cancer Res. 2015, 75, 4351–4363. [CrossRef] 273. Ariyoshi, M.; Schwabe, J.W. A conserved structural motif reveals the essential transcriptional repression function of Spen proteins and their role in developmental signaling. Genes Dev. 2003, 17, 1909–1920. [CrossRef] [PubMed] 274. Hiriart, E.; Gruffat, H.; Buisson, M.; Mikaelian, I.; Keppler, S.; Meresse, P.; Mercher, T.; Bernard, O.A.; Sergeant, A.; Manet, E. Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J. Biol. Chem. 2005, 280, 36935–36945. [CrossRef] 275. Bartkowiak, B.; Greenleaf, A.L. Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex. J. Biol. Chem. 2015, 290, 1786–1795. [CrossRef] [PubMed] 276. Ekumi, K.M.; Paculova, H.; Lenasi, T.; Pospichalova, V.; Bosken, C.A.; Rybarikova, J.; Bryja, V.; Geyer, M.; Blazek, D.; Barboric, M. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 2015, 43, 2575–2589. [CrossRef] 277. Blazek, D.; Kohoutek, J.; Bartholomeeusen, K.; Johansen, E.; Hulinkova, P.; Luo, Z.; Cimermancic, P.; Ule, J.; Peterlin, B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011, 25, 2158–2172. [CrossRef] 278. Krajewska, M.; Dries, R.; Grassetti, A.V.; Dust, S.; Gao, Y.; Huang, H.; Sharma, B.; Day, D.S.; Kwiatkowski, N.; Pomaville, M.; et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 2019, 10, 1757. [CrossRef] [PubMed] 279. Tien, J.F.; Mazloomian, A.; Cheng, S.G.; Hughes, C.S.; Chow, C.C.T.; Canapi, L.T.; Oloumi, A.; Trigo-Gonzalez, G.; Bashashati, A.; Xu, J.; et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 2017, 45, 6698–6716. [CrossRef] [PubMed] 280. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [CrossRef] 281. Schneeweiss, A.; Park-Simon, T.-W.; Albanell, J.; Lassen, U.; Cortés, J.; Dieras, V.; May, M.; Schindler, C.; Marmé, F.; Cejalvo, J.M.; et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investig. New Drugs 2018, 36, 848–859. [CrossRef] 282. Duncan, R.; Bazar, L.; Michelotti, G.; Tomonaga, T.; Krutzsch, H.; Avigan, M.; Levens, D. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 1994, 8, 465–480. [CrossRef] 283. Hsiao, H.H.; Nath, A.; Lin, C.Y.; Folta-Stogniew, E.J.; Rhoades, E.; Braddock, D.T. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 2010, 49, 4620–4634. [CrossRef] [PubMed] 284. Jacob, A.G.; Singh, R.K.; Mohammad, F.; Bebee, T.W.; Chandler, D.S. The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA. J. Biol. Chem. 2014, 289, 17350–17364. [CrossRef] [PubMed] 285. Lee, S.C.; Abdel-Wahab, O. Therapeutic targeting of splicing in cancer. Nat. Med. 2016, 22, 976–986. [CrossRef] [PubMed] 286. Urbanski, L.M.; Leclair, N.; Anczukow, O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip. Rev. RNA 2018, 9, e1476. [CrossRef] 287. Zhang, Y.; Qian, J.; Gu, C.; Yang, Y. Alternative splicing and cancer: A systematic review. Signal Transduct. Target. Ther. 2021, 6, 78. [CrossRef] 288. Elman, J.S.; Ni, T.K.; Mengwasser, K.E.; Jin, D.; Wronski, A.; Elledge, S.J.; Kuperwasser, C. Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing. Cell Rep. 2019, 28, 3435–3449.e3435. [CrossRef] 289. Sailo, B.L.; Banik, K.; Girisa, S.; Bordoloi, D.; Fan, L.; Halim, C.E.; Wang, H.; Kumar, A.P.; Zheng, D.; Mao, X.; et al. FBXW7 in Cancer: What Has Been Unraveled Thus Far? Cancers 2019, 11, 246. [CrossRef] 290. Wyatt, D.W.; Feng, W.; Conlin, M.P.; Yousefzadeh, M.J.; Roberts, S.A.; Mieczkowski, P.; Wood, R.D.; Gupta, G.P.; Ramsden, D.A. Essential Roles for Polymerase theta-Mediated End Joining in the Repair of Chromosome Breaks. Mol. Cell 2016, 63, 662–673. [CrossRef] 291. Feng, W.; Simpson, D.A.; Carvajal-Garcia, J.; Price, B.A.; Kumar, R.J.; Mose, L.E.; Wood, R.D.; Rashid, N.; Purvis, J.E.; Parker, J.S.; et al. Genetic determinants of cellular addiction to DNA polymerase theta. Nat. Commun. 2019, 10, 4286. [CrossRef]